Perkenalan
Halaman ini memberikan analisis komprehensif tentang riwayat insider trading yang diketahui di Perceptive Life Sciences Master Fund Ltd. Insider adalah pejabat, direktur, atau investor penting dalam suatu perusahaan. Adalah ilegal bagi insider untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik dan non-publik. Hal ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan ke SEC melalui Formulir 4. Meskipun ada pembatasan ini, penelitian akademis menunjukkan bahwa insider – secara umum – cenderung mengungguli pasar di perusahaan mereka sendiri.
Profitabilitas Perdagangan Rata-rata
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari seluruh pembelian pasar terbuka yang dilakukan oleh insider dalam 3 tahun terakhir. Untuk menghitungnya, kami memeriksa setiap pembelian pasar terbuka dan tidak terencana yang dilakukan oleh insider, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata perdagangan tersebut selama 3, 6, dan 12 bulan, merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami menghitung rata-rata semua metrik kinerja untuk menghitung metrik kinerja bagi insider. Daftar ini hanya mencakup insider yang telah melakukan setidaknya tiga perdagangan dalam 2 tahun terakhir.
Jika profitabilitas perdagangan insider ini adalah "T/A", maka insider tersebut belum melakukan pembelian di pasar terbuka dalam 3 tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang dapat diandalkan.
Frekuensi Pembaruan: Harian
Perusahaan dengan Posisi Insider yang Dilaporkan
Pengajuan SEC menunjukkan Perceptive Life Sciences Master Fund Ltd telah melaporkan kepemilikan atau perdagangan di perusahaan berikut:
Bagaimana Menafsirkan Grafik
Bagan berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka dan tidak terencana yang dilakukan oleh Perceptive Life Sciences Master Fund Ltd. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham dipetakan sebagai persentase perubahan kumulatif harga saham. Misalnya, jika perdagangan insider dilakukan pada tanggal 1 Januari 2019, grafik akan menunjukkan persentase perubahan harian sekuritas hingga hari ini. Jika harga saham naik dari $10 menjadi $15 selama waktu ini, persentase perubahan harga saham kumulatif akan menjadi 50%. Perubahan harga dari $10 menjadi $20 adalah 100%, dan perubahan harga dari $10 menjadi $5 adalah -50%.
Pada akhirnya, kami mencoba untuk menentukan seberapa dekat korelasi perdagangan insider dengan keuntungan berlebih (positif atau negatif) pada harga saham untuk melihat apakah insider mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi insider. Pertimbangkan situasi di mana insider melakukan hal ini. Dalam situasi ini, kita mengharapkan (a) keuntungan positif setelah pembelian, atau (b) keuntungan negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, yang menunjukkan keuntungan positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, yang menunjukkan keuntungan negatif setelah setiap transaksi penjualan.
Namun, hal ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam kenaikan non-siklus selama bertahun-tahun, maka kita perkirakan semua lahan pasca pembelian akan miring ke atas. Demikian pula, penurunan non-siklus selama bertahun-tahun akan mengakibatkan penurunan pasca-perdagangan. Tak satu pun dari grafik ini menunjukkan aktivitas insider trading.
Indikator terkuat adalah situasi di mana harga saham sangat bersiklus, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat memberi isyarat kepada insider yang mengatur waktu perdagangan demi keuntungan finansial mereka.
Pembelian Insider ACRV / Acrivon Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-11 | ACRV | PERCEPTIVE ADVISORS LLC | 2.353.000 | 8,5000 | 2.353.000 | 8,5000 | 20.000.500 | 7 | 10.5400 | 4.800.120 | 24,00 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider ACRV / Acrivon Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider ADMA / ADMA Biologics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider ADMA / ADMA Biologics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider ALDX / Aldeyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider ALDX / Aldeyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider ANIP / ANI Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider ANIP / ANI Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider CRNX / Crinetics Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider CRNX / Crinetics Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider CYPH / Cypherpunk Technologies Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-22 | LPTX | PERCEPTIVE ADVISORS LLC | 1.750.000 | 2,0000 | 175.000 | 20,0000 | 3.500.000 | 240 | 301 | 49.175.000 | 1.405,00 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider CYPH / Cypherpunk Technologies Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider IMTX / Immatics N.V. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider IMTX / Immatics N.V. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider LONA / LeonaBio, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider LONA / LeonaBio, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider LYRA / Lyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider LYRA / Lyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider MGTX / MeiraGTx Holdings plc - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider MGTX / MeiraGTx Holdings plc - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider NAUT / Nautilus Biotechnology, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider NAUT / Nautilus Biotechnology, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider OBIO / Orchestra BioMed Holdings, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-01 | OBIO | PERCEPTIVE ADVISORS LLC | 700.000 | 2,7500 | 700.000 | 2,7500 | 1.925.000 | 116 | 5.3500 | 1.820.000 | 94,55 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider OBIO / Orchestra BioMed Holdings, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider SCYX / SCYNEXIS, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider SCYX / SCYNEXIS, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider SLDB / Solid Biosciences Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider SLDB / Solid Biosciences Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider TLPH / Talphera, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider TLPH / Talphera, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider VRCA / Verrica Pharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider VRCA / Verrica Pharmaceuticals Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider VYNE / VYNE Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada ACRV / Acrivon Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider VYNE / VYNE Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di ACRV / Acrivon Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Riwayat Insider Trading
Tabel ini menunjukkan daftar lengkap perdagangan insider yang dilakukan oleh Perceptive Life Sciences Master Fund Ltd sebagaimana diungkapkan kepada Securities Exchange Commission (SEC).
| Tanggal Berkas | Tanggal Trans | Formulir | Kode | Keamanan | Kode | Saham | Sisa Saham | Persen Mengubah |
Saham Harga |
Trans Nilai |
Tersisa Nilai |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
A - Award | 555.555 | 10.786.658 | 5,43 | 9,00 | 4.999.995 | 97.079.922 | |
| 2026-03-18 | 3 | IMTX |
Immatics N.V.
Ordinary Shares, nominal value EUR 0.01 per share |
10.383.456 | ||||||||
| 2026-01-02 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
D - Sale to Issuer | -2.300.000 | 10.231.103 | -18,35 | 7,91 | -18.193.000 | 80.928.025 | |
| 2025-12-23 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
A - Award | 329.756 | 329.756 | 6,35 | 2.093.951 | 2.093.951 | ||
| 2025-12-23 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
A - Award | 989.270 | 1.529.566 | 183,10 | 6,35 | 6.281.864 | 9.712.744 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -3.213 | 14.026 | -18,64 | 3,90 | -12.531 | 54.703 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -28.597 | 124.859 | -18,64 | 3,90 | -111.531 | 486.963 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -883 | 17.239 | -4,87 | 4,06 | -3.584 | 69.980 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -7.862 | 153.456 | -4,87 | 4,06 | -31.915 | 622.939 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -537 | 18.122 | -2,88 | 4,31 | -2.317 | 78.189 | |
| 2025-11-13 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -4.783 | 161.318 | -2,88 | 4,31 | -20.637 | 696.023 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -1.869 | 18.659 | -9,10 | 4,54 | -8.485 | 84.708 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -16.633 | 166.101 | -9,10 | 4,54 | -75.510 | 754.065 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -1.993 | 20.528 | -8,85 | 4,75 | -9.460 | 97.440 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -17.746 | 182.734 | -8,85 | 4,75 | -84.235 | 867.383 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -3.247 | 22.521 | -12,60 | 5,18 | -16.819 | 116.657 | |
| 2025-11-10 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
S - Sale | -28.902 | 200.480 | -12,60 | 5,18 | -149.709 | 1.038.466 | |
| 2025-08-05 |
|
4 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock |
P - Purchase | 700.000 | 5.292.556 | 15,24 | 2,75 | 1.925.000 | 14.554.529 | |
| 2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -298.886 | 3.104.139 | -8,78 | 1,34 | -400.507 | 4.159.546 | |
| 2025-05-01 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -437.881 | 3.403.025 | -11,40 | 1,41 | -617.412 | 4.798.265 | |
| 2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -250.000 | 3.840.906 | -6,11 | 1,41 | -352.500 | 5.415.677 | |
| 2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -215.283 | 4.090.906 | -5,00 | 1,56 | -335.841 | 6.381.813 | |
| 2025-04-29 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
S - Sale | -1.054.669 | 4.306.189 | -19,67 | 1,95 | -2.056.605 | 8.397.069 | |
| 2025-04-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -3.400.000 | 5.875.851 | -36,65 | 1,42 | -4.828.000 | 8.343.708 | |
| 2025-02-21 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 5.000.000 | 11.833.539 | 73,17 | 4,03 | 20.150.000 | 47.689.162 | |
| 2025-02-14 |
|
4 | ADGM |
Adagio Medical Holdings, Inc.
Common Stock |
A - Award | 64.167 | 9.675.684 | 0,67 | ||||
| 2024-08-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.250.000 | 12.531.103 | 11,08 | 4,00 | 5.000.000 | 50.124.412 | |
| 2024-08-01 | 3 | ADGM |
Adagio Medical Holdings, Inc.
Common stock |
7.160.397 | ||||||||
| 2024-07-17 | 3 | OBIO |
Orchestra BioMed Holdings, Inc.
Common Stock, $0.0001 par value per share |
4.592.556 | ||||||||
| 2024-04-15 |
|
4 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
P - Purchase | 2.353.000 | 5.360.858 | 78,23 | 8,50 | 20.000.500 | 45.567.293 | |
| 2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 37.712 | 9.275.851 | 0,41 | 4,74 | 178.755 | 43.967.534 | |
| 2024-04-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 140.281 | 9.238.139 | 1,54 | 4,67 | 655.112 | 43.142.109 | |
| 2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 309.847 | 9.097.858 | 3,53 | 4,09 | 1.267.274 | 37.210.239 | |
| 2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 186.051 | 8.788.011 | 2,16 | 3,44 | 640.015 | 30.230.758 | |
| 2024-04-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 8.374 | 8.601.960 | 0,10 | 3,25 | 27.216 | 27.956.370 | |
| 2024-02-21 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
G - Gift | -170.317 | 0 | -100,00 | ||||
| 2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19.218 | 17.082 | -52,94 | 4,76 | -91.478 | 81.310 | |
| 2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
F - Taxes | -19.218 | 17.082 | -52,94 | 4,76 | -91.478 | 81.310 | |
| 2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36.300 | 36.300 | 2,52 | 91.476 | 91.476 | ||
| 2024-02-20 |
|
4 | LIAN |
LianBio
Ordinary Shares |
M - Exercise | 36.300 | 36.300 | 2,52 | 91.476 | 91.476 | ||
| 2024-02-05 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 2.481.350 | 4.873.721 | 103,72 | 12,09 | 29.999.522 | 58.923.287 | |
| 2024-01-12 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 3.410.713 | 6.833.539 | 99,65 | 5,53 | 18.861.243 | 37.789.471 | |
| 2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 163.954 | 5.402.964 | 3,13 | 2,38 | 390.211 | 12.859.054 | |
| 2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 409.598 | 5.239.010 | 8,48 | 2,44 | 999.419 | 12.783.184 | |
| 2023-12-29 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 32.134 | 4.829.412 | 0,67 | 2,28 | 73.266 | 11.011.059 | |
| 2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 115.774 | 7.099.182 | 1,66 | 7,24 | 838.204 | 51.398.078 | |
| 2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 126.116 | 6.983.408 | 1,84 | 7,08 | 892.901 | 49.442.529 | |
| 2023-12-29 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 79.726 | 6.857.292 | 1,18 | 7,20 | 574.027 | 49.372.502 | |
| 2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 54.652 | 6.777.566 | 0,81 | 6,49 | 354.691 | 43.986.403 | |
| 2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 250.000 | 6.722.914 | 3,86 | 6,67 | 1.667.500 | 44.841.836 | |
| 2023-12-26 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 200.000 | 6.472.914 | 3,19 | 6,17 | 1.234.000 | 39.937.879 | |
| 2023-12-22 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 740.000 | 2.392.371 | 44,78 | 6,20 | 4.588.000 | 14.832.700 | |
| 2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 277.008 | 6.272.914 | 4,62 | 5,36 | 1.484.763 | 33.622.819 | |
| 2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 456.923 | 5.995.906 | 8,25 | 5,41 | 2.471.953 | 32.437.851 | |
| 2023-12-19 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 500.000 | 5.538.983 | 9,92 | 5,97 | 2.985.000 | 33.067.729 | |
| 2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333.333 | 333.333 | 15,00 | 4.999.995 | 4.999.995 | ||
| 2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
P - Purchase | 333.333 | 333.333 | 15,00 | 4.999.995 | 4.999.995 | ||
| 2023-11-14 |
|
4 | CRGX |
CARGO Therapeutics, Inc.
Common Stock |
C - Conversion | 2.579.502 | 2.579.502 | |||||
| 2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 460.546 | 1.611.699 | 40,01 | 6,51 | 2.999.997 | 10.498.607 | |
| 2023-10-18 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 614.062 | 1.652.371 | 59,14 | 6,51 | 4.000.000 | 10.763.545 | |
| 2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -306.499 | 8.593.586 | -3,44 | 1,74 | -533.308 | 14.952.840 | |
| 2023-10-18 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
S - Sale | -2.450.000 | 8.900.085 | -21,59 | 1,60 | -3.920.000 | 14.240.136 | |
| 2023-10-17 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 876.808 | 10.794.876 | 8,84 | 22,81 | 19.999.990 | 246.231.122 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 250.000 | 3.074.542 | 8,85 | 20,00 | 5.000.000 | 61.490.840 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 36.939 | 2.824.542 | 1,33 | 21,00 | 775.719 | 59.315.382 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 117.996 | 2.787.603 | 4,42 | 20,03 | 2.363.460 | 55.835.688 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 88.685 | 2.669.607 | 3,44 | 19,11 | 1.694.770 | 51.016.190 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 52.691 | 2.580.922 | 2,08 | 18,24 | 961.084 | 47.076.017 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 75.477 | 2.528.231 | 3,08 | 17,28 | 1.304.243 | 43.687.832 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.769 | 2.452.754 | 1,15 | 16,00 | 444.304 | 39.244.064 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 3.326 | 2.424.985 | 0,14 | 14,61 | 48.593 | 35.429.031 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 30.511 | 2.421.659 | 1,28 | 13,92 | 424.713 | 33.709.493 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 42.838 | 2.391.148 | 1,82 | 12,84 | 550.040 | 30.702.340 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 77.837 | 2.348.310 | 3,43 | 11,81 | 919.255 | 27.733.541 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 37.911 | 2.270.473 | 1,70 | 11,05 | 418.917 | 25.088.727 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5.419 | 2.232.562 | 0,24 | 9,52 | 51.589 | 21.253.990 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 13.687 | 2.227.143 | 0,62 | 8,30 | 113.602 | 18.485.287 | |
| 2023-09-28 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 5.703 | 2.213.456 | 0,26 | 7,65 | 43.628 | 16.932.938 | |
| 2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 200 | 2.207.753 | 0,01 | 5,93 | 1.186 | 13.091.975 | |
| 2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 78.468 | 2.207.553 | 3,69 | 5,98 | 469.239 | 13.201.167 | |
| 2023-06-06 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 64.630 | 2.129.085 | 3,13 | 5,93 | 383.256 | 12.625.474 | |
| 2023-06-02 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3.610.832 | 11.469.117 | 45,95 | 2,49 | 8.999.999 | 28.586.774 | |
| 2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 7.500 | 2.064.455 | 0,36 | 5,59 | 41.925 | 11.540.303 | |
| 2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 10.000 | 2.056.955 | 0,49 | 5,28 | 52.800 | 10.860.722 | |
| 2023-06-01 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 17.500 | 2.046.955 | 0,86 | 5,34 | 93.450 | 10.930.740 | |
| 2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 22.500 | 2.029.455 | 1,12 | 5,27 | 118.575 | 10.695.228 | |
| 2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 37.500 | 2.006.955 | 1,90 | 5,18 | 194.250 | 10.396.027 | |
| 2023-05-26 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
210859 |
P - Purchase | 25.000 | 1.969.455 | 1,29 | 5,48 | 137.000 | 10.792.613 | |
| 2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.500 | 1.944.455 | 1,43 | 5,45 | 149.875 | 10.597.280 | |
| 2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 27.300 | 1.916.955 | 1,44 | 5,12 | 139.776 | 9.814.810 | |
| 2023-05-23 |
|
4 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
P - Purchase | 25.200 | 1.889.655 | 1,35 | 4,62 | 116.424 | 8.730.206 | |
| 2023-05-18 | 3 | SLNO |
SOLENO THERAPEUTICS INC
Common Stock |
1.864.455 | ||||||||
| 2023-05-15 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 4.347.826 | 11.281.103 | 62,71 | 5,75 | 25.000.000 | 64.866.342 | |
| 2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4.251.563 | 41.440.729 | -9,30 | 0,11 | -467.672 | 4.558.480 | |
| 2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1.832.563 | 45.691.816 | -3,86 | 0,13 | -238.233 | 5.939.936 | |
| 2023-04-06 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -4.810.623 | 47.524.379 | -9,19 | 0,16 | -769.700 | 7.603.901 | |
| 2022-12-21 |
|
4 | ATXS |
Astria Therapeutics, Inc.
Common Stock |
P - Purchase | 908.265 | 1.038.309 | 698,43 | 11,01 | 9.999.998 | 11.431.782 | |
| 2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 73.107 | 73.107 | |||||
| 2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 365.536 | 3.422.826 | 11,96 | ||||
| 2022-12-06 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 2.163.120 | 3.057.290 | 241,91 | 7,05 | 15.249.996 | 21.553.894 | |
| 2022-11-18 | 3 | ACRV |
Acrivon Therapeutics, Inc.
Common Stock |
3.007.858 | ||||||||
| 2022-11-02 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares, nil par value |
S - Sale | -8.255.607 | 7.945.211 | -50,96 | 0,08 | -660.449 | 635.617 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -406 | 1.939.723 | -0,02 | 22,79 | -9.253 | 44.206.287 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -178.726 | 1.940.129 | -8,44 | 22,01 | -3.933.759 | 42.702.239 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -7.240 | 2.118.855 | -0,34 | 23,23 | -168.185 | 49.221.002 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -89.979 | 2.126.095 | -4,06 | 22,26 | -2.002.933 | 47.326.875 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -5.415 | 2.216.074 | -0,24 | 24,78 | -134.184 | 54.914.314 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -38.310 | 2.221.489 | -1,70 | 24,18 | -926.336 | 53.715.604 | |
| 2022-10-13 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
S - Sale | -100.340 | 2.259.799 | -4,25 | 23,23 | -2.330.898 | 52.495.131 | |
| 2022-08-22 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 998.240 | 3.728.491 | 36,56 | 2,40 | 2.395.776 | 8.948.378 | |
| 2022-08-18 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 1.425.000 | 6.511.727 | 28,01 | 35,00 | 49.875.000 | 227.910.445 | |
| 2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 15.000 | 11.350.085 | 0,13 | 7,85 | 117.750 | 89.098.167 | |
| 2022-08-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 11.335.085 | 0,89 | 7,50 | 750.000 | 85.013.138 | |
| 2022-08-10 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 97.000 | 11.235.085 | 0,87 | 7,24 | 702.280 | 81.342.015 | |
| 2022-08-09 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 141.000 | 11.138.085 | 1,28 | 6,95 | 979.950 | 77.409.691 | |
| 2022-08-08 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 95.100 | 10.997.085 | 0,87 | 6,17 | 586.767 | 67.852.014 | |
| 2022-08-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 100.000 | 10.901.985 | 0,93 | 5,84 | 584.000 | 63.667.592 | |
| 2022-08-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 412.406 | 10.801.985 | 3,97 | 5,59 | 2.305.350 | 60.383.096 | |
| 2022-08-03 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 144.185 | 10.389.579 | 1,41 | 5,05 | 728.134 | 52.467.374 | |
| 2022-08-02 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 222.123 | 10.245.394 | 2,22 | 5,03 | 1.117.279 | 51.534.332 | |
| 2022-08-01 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 119.392 | 10.023.271 | 1,21 | 5,00 | 596.960 | 50.116.355 | |
| 2022-07-05 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.428.571 | 5.038.983 | 39,57 | 2,10 | 2.999.999 | 10.581.864 | |
| 2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1.101.362 | 4.797.278 | 29,80 | 2,99 | 3.293.072 | 14.343.861 | |
| 2022-07-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 270.000 | 3.695.916 | 7,88 | 2,99 | 807.300 | 11.050.789 | |
| 2022-05-27 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 69.000 | 2.730.251 | 2,59 | 3,13 | 215.970 | 8.545.686 | |
| 2022-05-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13.871 | 13.871 | |||||
| 2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 120.000 | 2.661.251 | 4,72 | 2,63 | 315.600 | 6.999.090 | |
| 2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 42.551 | 2.541.251 | 1,70 | 2,47 | 105.101 | 6.276.890 | |
| 2022-05-25 |
|
4 | LIAN |
LianBio
American Depositary Shares |
P - Purchase | 8.700 | 2.498.700 | 0,35 | 2,49 | 21.663 | 6.221.763 | |
| 2022-04-18 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 157.515 | 5.321.032 | 3,05 | 22,22 | 3.499.983 | 118.233.331 | |
| 2022-04-14 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 5.924.170 | 7.858.285 | 306,30 | 4,22 | 24.999.997 | 33.161.963 | |
| 2021-12-10 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 200.000 | 9.111.151 | 2,24 | 5,36 | 1.072.000 | 48.835.769 | |
| 2021-12-03 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -2.707.463 | 52.334.993 | -4,92 | 3,31 | -8.961.703 | 173.228.827 | |
| 2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 20.000 | 27.858.895 | 0,07 | 13,51 | 270.200 | 376.373.671 | |
| 2021-11-05 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 2.250.000 | 27.838.895 | 8,79 | 16,00 | 36.000.000 | 445.422.320 | |
| 2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -423.579 | 0 | -100,00 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -500.000 | 0 | -100,00 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Series Seed Preferred Shares |
C - Conversion | -2.500.000 | 0 | -100,00 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Series A Preferred Shares |
C - Conversion | -635.369 | 0 | -100,00 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2.477.005 | 2.477.005 | |||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 2.923.000 | 4.330.675 | 207,65 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14.619.500 | 21.653.385 | 207,84 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 14.619.500 | 21.653.385 | 207,84 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
C - Conversion | 3.715.510 | 10.969.395 | 51,22 | ||||
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 100.000 | 7.253.885 | 1,40 | 13,50 | 1.350.000 | 97.927.448 | |
| 2021-11-03 |
|
4 | LIAN |
LianBio
Ordinary Shares |
P - Purchase | 120.000 | 7.153.885 | 1,71 | 15,50 | 1.860.000 | 110.885.218 | |
| 2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7.033.885 | ||||||||
| 2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
7.033.885 | ||||||||
| 2021-10-29 | 3 | LIAN |
LianBio
Ordinary Shares |
1.406.775 | ||||||||
| 2021-10-25 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1.200.000 | 5.163.517 | 30,28 | 19,80 | 23.760.000 | 102.237.637 | |
| 2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
P - Purchase | 2.687.280 | 2.687.280 | |||||
| 2021-10-15 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 5.734.560 | 21.654.485 | 36,02 | 0,85 | 4.874.376 | 18.406.312 | |
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -24.629 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -40.373 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock |
C - Conversion | -325.014 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
P - Purchase | 850.000 | 3.554.587 | 31,43 | 15,00 | 12.750.000 | 53.318.805 | |
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 204.949 | 204.949 | |||||
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 335.962 | 335.962 | |||||
| 2021-10-14 |
|
4 | ISO |
IsoPlexis Corp
Common Stock |
C - Conversion | 2.704.587 | 2.704.587 | |||||
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -7.306 | 2.487.019 | -0,29 | 13,40 | -97.900 | 33.326.055 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -9.351 | 2.494.325 | -0,37 | 13,15 | -122.966 | 32.800.374 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -12.475 | 2.503.676 | -0,50 | 12,03 | -150.074 | 30.119.222 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -2.462 | 2.516.151 | -0,10 | 13,66 | -33.631 | 34.370.623 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -5.038 | 2.518.613 | -0,20 | 12,90 | -64.990 | 32.490.108 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -286 | 2.523.651 | -0,01 | 15,05 | -4.304 | 37.980.948 | |
| 2021-10-13 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
S - Sale | -13.082 | 2.523.937 | -0,52 | 14,80 | -193.614 | 37.354.268 | |
| 2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -137.495 | 13.262.375 | -1,03 | 1,12 | -153.994 | 14.853.860 | |
| 2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -82.505 | 13.399.870 | -0,61 | 1,16 | -95.706 | 15.543.849 | |
| 2021-09-30 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -40.603 | 13.482.375 | -0,30 | 1,22 | -49.536 | 16.448.498 | |
| 2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250.000 | 13.522.978 | -1,82 | 1,23 | -307.500 | 16.633.263 | |
| 2021-09-29 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -250.000 | 13.772.978 | -1,78 | 1,26 | -315.000 | 17.353.952 | |
| 2021-09-28 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Warrants (right to buy) |
P - Purchase | 3.508.771 | 3.508.771 | 2,85 | 9.996.489 | 9.996.489 | ||
| 2021-09-28 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -780.000 | 14.022.978 | -5,27 | 1,27 | -990.600 | 17.809.182 | |
| 2021-08-31 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 68.047 | 5.086.727 | 1,36 | 30,23 | 2.057.061 | 153.771.757 | |
| 2021-08-31 |
|
4 | LABP |
Landos Biopharma, Inc.
Stock Option (Right to Buy) |
A - Award | 25.291 | 25.291 | |||||
| 2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 61.387 | 5.018.680 | 1,24 | 28,57 | 1.753.827 | 143.383.688 | |
| 2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 69.761 | 4.957.293 | 1,43 | 27,73 | 1.934.473 | 137.465.735 | |
| 2021-08-25 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 44.437 | 4.887.532 | 0,92 | 25,78 | 1.145.586 | 126.000.575 | |
| 2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -350.352 | 14.802.978 | -2,31 | 1,24 | -434.436 | 18.355.693 | |
| 2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -552.380 | 15.153.330 | -3,52 | 1,29 | -712.570 | 19.547.796 | |
| 2021-08-19 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
S - Sale | -879.092 | 15.705.710 | -5,30 | 1,35 | -1.186.774 | 21.202.708 | |
| 2021-08-18 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250.000 | 4.935.057 | -4,82 | 1,74 | -435.000 | 8.586.999 | |
| 2021-08-17 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -250.000 | 5.185.057 | -4,60 | 1,84 | -460.000 | 9.540.505 | |
| 2021-08-16 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -338.897 | 5.435.057 | -5,87 | 2,23 | -755.740 | 12.120.177 | |
| 2021-07-09 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common Stock |
P - Purchase | 200.000 | 4.843.095 | 4,31 | 25,00 | 5.000.000 | 121.077.375 | |
| 2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -145.548 | 0 | -100,00 | 3,80 | -553.082 | ||
| 2021-06-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -500.709 | 0 | -100,00 | 3,80 | -1.902.694 | ||
| 2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2021-06-14 |
|
4 | MGTX |
MeiraGTx Holdings plc
Restricted Share Units |
A - Award | 15.000 | 15.000 | |||||
| 2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
J - Other | 2.914.113 | 8.911.151 | 48,59 | ||||
| 2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 5.500.000 | 5.997.038 | 1.106,56 | 10,00 | 55.000.000 | 59.970.380 | |
| 2021-06-11 |
|
4 | NAUT |
Nautilus Biotechnology, Inc.
Common Stock |
P - Purchase | 7.063 | 497.038 | 1,44 | 10,05 | 70.983 | 4.995.232 | |
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -465.936 | 0 | -100,00 | ||||
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Warrant (right to buy) |
X - Other | -1.602.888 | 0 | -100,00 | ||||
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -320.388 | 145.548 | -68,76 | 4,00 | -1.281.552 | 582.192 | |
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
S - Sale | -1.102.179 | 500.709 | -68,76 | 4,00 | -4.408.716 | 2.002.836 | |
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 465.936 | 465.936 | 2,75 | 1.281.324 | 1.281.324 | ||
| 2021-06-11 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
X - Other | 1.602.888 | 1.602.888 | 2,75 | 4.407.942 | 4.407.942 | ||
| 2021-06-03 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 330.050 | 489.975 | 206,38 | 10,05 | 3.317.002 | 4.924.249 | |
| 2021-06-01 |
|
4 | ATHA |
Athira Pharma, Inc.
Stock Option (Right to Buy) |
A - Award | 13.871 | 13.871 | |||||
| 2021-05-24 |
|
4 | ARYA |
ARYA Sciences Acquisition Corp III
Class A Ordinary Shares |
P - Purchase | 159.925 | 159.925 | 10,05 | 1.607.246 | 1.607.246 | ||
| 2021-05-07 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
S - Sale | -1.000.000 | 5.773.954 | -14,76 | 3,67 | -3.670.000 | 21.190.411 | |
| 2021-05-04 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1.200.000 | 9.903.879 | 13,79 | 12,50 | 15.000.000 | 123.798.488 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.195.792 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -949.992 | 0 | -100,00 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
P - Purchase | 550.000 | 2.537.019 | 27,68 | 17,00 | 9.350.000 | 43.129.323 | |
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 1.107.316 | 1.987.019 | 125,87 | ||||
| 2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock |
C - Conversion | 879.703 | 879.703 | |||||
| 2021-04-09 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 304.136 | 3.963.517 | 8,31 | 16,44 | 4.999.996 | 65.160.219 | |
| 2021-04-06 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 450.000 | 450.000 | |||||
| 2021-03-23 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2.608.695 | 13.412.552 | 24,15 | 5,75 | 14.999.996 | 77.122.174 | |
| 2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-2 Convertible Preferred Stock |
C - Conversion | -14.462.623 | 0 | -100,00 | ||||
| 2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Series D-1 Convertible Preferred Stock |
C - Conversion | -10.177.703 | 0 | -100,00 | ||||
| 2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
P - Purchase | 850.000 | 3.314.032 | 34,50 | 19,00 | 16.150.000 | 62.966.608 | |
| 2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1.446.262 | 2.464.032 | 142,10 | ||||
| 2021-03-16 |
|
4 | RXDX |
Prometheus Biosciences, Inc.
Common Stock |
C - Conversion | 1.017.770 | 1.017.770 | |||||
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34.951 | 7.299.751 | 0,48 | 14,60 | 510.285 | 106.576.365 | |
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 64.730 | 7.264.800 | 0,90 | 13,80 | 893.274 | 100.254.240 | |
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1.771 | 7.200.070 | 0,02 | 13,10 | 23.200 | 94.320.917 | |
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 86.671 | 7.198.299 | 1,22 | 12,53 | 1.085.988 | 90.194.686 | |
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 34.611 | 7.111.628 | 0,49 | 11,38 | 393.873 | 80.930.327 | |
| 2021-02-09 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 27.453 | 7.077.017 | 0,39 | 11,14 | 305.826 | 78.837.969 | |
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -1.770.600 | 0 | -100,00 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2.857.795 | 0 | -100,00 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series B Preferred Stock |
C - Conversion | -2.857.795 | 0 | -100,00 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2.941.769 | 0 | -100,00 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Series A Preferred Stock |
C - Conversion | -2.941.769 | 0 | -100,00 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
P - Purchase | 1.250.000 | 7.049.564 | 21,55 | 16,00 | 20.000.000 | 112.793.024 | |
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 1.770.600 | 1.770.600 | |||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.857.795 | 5.799.564 | 97,15 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.857.795 | 5.799.564 | 97,15 | ||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.941.769 | 2.941.769 | |||||
| 2021-02-08 |
|
4 | LABP |
Landos Biopharma, Inc.
Common Stock |
C - Conversion | 2.941.769 | 2.941.769 | |||||
| 2021-02-03 | 3 | LABP |
Landos Biopharma, Inc.
Common Stock |
3.090.924 | ||||||||
| 2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
543.373 | ||||||||
| 2021-02-03 | 3 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
1.933.551 | ||||||||
| 2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 1.617 | 30.920 | 5,52 | 3.009,53 | 4.866.410 | 93.054.668 | |
| 2021-02-03 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock |
A - Award | 4.851 | 4.851 | 3.009,53 | 14.599.230 | 14.599.230 | ||
| 2021-02-01 |
|
4 | VYNE |
VYNE Therapeutics Inc.
Common Stock |
P - Purchase | 4.219.409 | 27.095.819 | 18,44 | 2,37 | 9.999.999 | 64.217.091 | |
| 2021-01-27 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 311.111 | 3.425.916 | 9,99 | 22,50 | 6.999.998 | 77.083.110 | |
| 2021-01-26 | 3 | SCYX |
SCYNEXIS INC
Common Stock |
2.400.000 | ||||||||
| 2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -33.849 | 1.800.000 | -1,85 | 8,95 | -302.949 | 16.110.000 | |
| 2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -285.151 | 1.833.849 | -13,46 | 8,16 | -2.326.832 | 14.964.208 | |
| 2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -95.000 | 2.120.000 | -4,29 | 7,38 | -701.100 | 15.645.600 | |
| 2021-01-26 |
|
4 | SCYX |
SCYNEXIS INC
Common Stock |
S - Sale | -185.000 | 2.215.000 | -7,71 | 7,43 | -1.374.550 | 16.457.450 | |
| 2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -550.000 | 2.660.542 | -17,13 | 1,48 | -814.000 | 3.937.602 | |
| 2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -674.352 | 3.210.542 | -17,36 | 1,68 | -1.132.911 | 5.393.711 | |
| 2021-01-22 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
S - Sale | -325.648 | 3.884.894 | -7,73 | 1,80 | -586.166 | 6.992.809 | |
| 2021-01-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 1.368.421 | 8.703.879 | 18,65 | 9,50 | 13.000.000 | 82.686.850 | |
| 2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50.000 | 7.335.458 | 0,69 | 7,60 | 380.000 | 55.749.481 | |
| 2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 152.668 | 7.285.458 | 2,14 | 10,21 | 1.558.740 | 74.384.526 | |
| 2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 347.332 | 7.132.790 | 5,12 | 9,21 | 3.198.928 | 65.692.996 | |
| 2021-01-11 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 500.000 | 6.785.458 | 7,95 | 8,13 | 4.065.000 | 55.165.774 | |
| 2020-12-15 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
A - Award | 4.054.054 | 10.803.857 | 60,06 | 3,70 | 15.000.000 | 39.974.271 | |
| 2020-11-24 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 500.000 | 6.933.277 | 7,77 | 12,85 | 6.425.000 | 89.092.609 | |
| 2020-10-29 |
|
4 | CERE |
Cerevel Therapeutics Holdings, Inc.
Common stock |
P - Purchase | 3.000.000 | 3.157.295 | 1.907,24 | 10,00 | 30.000.000 | 31.572.950 | |
| 2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 43.195 | 157.295 | 37,86 | 10,09 | 435.838 | 1.587.107 | |
| 2020-10-22 |
|
4 | ARYB |
ARYA Sciences Acquisition Corp II
Class A ordinary shares |
P - Purchase | 114.100 | 114.100 | 10,00 | 1.141.000 | 1.141.000 | ||
| 2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Series B Preferred Stock |
C - Conversion | -1.644.785 | 0 | -100,00 | ||||
| 2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
P - Purchase | 1.058.824 | 3.114.805 | 51,50 | 17,00 | 18.000.008 | 52.951.685 | |
| 2020-09-22 |
|
4 | ATHA |
Athira Pharma, Inc.
Common Stock |
C - Conversion | 1.644.785 | 2.055.981 | 400,00 | ||||
| 2020-09-17 | 3 | ATHA |
Athira Pharma, Inc.
Common Stock |
411.196 | ||||||||
| 2020-09-16 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.911.764 | 16.200.818 | 21,91 | 4,25 | 12.374.997 | 68.853.476 | |
| 2020-09-15 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 400.000 | 2.360.139 | 20,41 | 40,00 | 16.000.000 | 94.405.560 | |
| 2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1.800.000 | 13.532.467 | 15,34 | 11,00 | 19.800.000 | 148.857.137 | |
| 2020-09-14 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 200.000 | 11.732.467 | 1,73 | 11,24 | 2.248.000 | 131.872.929 | |
| 2020-07-13 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 3.200.000 | 6.285.458 | 103,71 | 4,25 | 13.600.000 | 26.713.196 | |
| 2020-06-24 |
|
4 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
P - Purchase | 1.750.000 | 8.476.496 | 26,02 | 2,00 | 3.500.000 | 16.952.992 | |
| 2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
| 2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
| 2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
| 2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
| 2020-06-11 | 3 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
40.347.416 | ||||||||
| 2020-06-11 |
|
4 | MNLO |
Menlo Therapeutics Inc.
Common Stock |
P - Purchase | 2.702.702 | 22.876.410 | 13,40 | 1,85 | 4.999.999 | 42.321.358 | |
| 2020-05-29 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
P - Purchase | 625.000 | 1.934.115 | 47,74 | 16,00 | 10.000.000 | 30.945.840 | |
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -339.604 | 0 | -100,00 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Warrants |
X - Other | -141.221 | 0 | -100,00 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -16.232.511 | 0 | -100,00 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -39.035.325 | 0 | -100,00 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -26.666.666 | 0 | -100,00 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -183.174 | 1.288.446 | -12,45 | 16,00 | -2.930.784 | 20.615.136 | |
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 339.604 | 1.471.620 | 30,00 | 8,63 | 2.930.783 | 12.700.081 | |
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
F - Taxes | -76.172 | 1.309.115 | -5,50 | 16,00 | -1.218.752 | 20.945.840 | |
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
X - Other | 141.221 | 1.385.287 | 11,35 | 8,63 | 1.218.737 | 11.955.027 | |
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 470.739 | 1.244.066 | 60,87 | ||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1.132.016 | 1.132.016 | |||||
| 2020-05-06 |
|
4 | LYRA |
Lyra Therapeutics, Inc.
Common Stock |
C - Conversion | 773.327 | 773.327 | |||||
| 2020-04-28 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 9.090.909 | 55.042.456 | 19,78 | 1,10 | 10.000.000 | 60.546.702 | |
| 2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
| 2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
| 2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
| 2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
| 2020-04-20 | 3 | LPTX |
LEAP THERAPEUTICS, INC.
Common Stock |
13.452.992 | ||||||||
| 2020-04-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1.071.428 | 3.659.381 | 41,40 | 14,00 | 14.999.992 | 51.231.334 | |
| 2020-03-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 500.000 | 16.584.802 | 3,11 | 2,10 | 1.050.000 | 34.828.084 | |
| 2020-03-17 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 1.000.000 | 15.919.925 | 6,70 | 1,75 | 1.750.000 | 27.859.869 | |
| 2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3.000.000 | 14.919.925 | 25,17 | 3,00 | 9.000.000 | 44.759.775 | |
| 2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700.000 | 700.000 | |||||
| 2020-02-25 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Warrants (right to buy) |
J - Other | 700.000 | 700.000 | |||||
| 2020-02-11 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4.563.700 | 16.084.802 | 39,61 | 3,50 | 15.972.950 | 56.296.807 | |
| 2020-02-04 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 255.809 | 1.960.139 | 15,01 | 21,00 | 5.371.989 | 41.162.919 | |
| 2019-12-27 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 73.698 | 11.532.467 | 0,64 | 14,39 | 1.060.514 | 165.952.200 | |
| 2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 153.237 | 11.458.769 | 1,36 | 14,30 | 2.191.289 | 163.860.397 | |
| 2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 189.322 | 11.305.532 | 1,70 | 14,14 | 2.677.013 | 159.860.222 | |
| 2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 120.931 | 11.116.210 | 1,10 | 13,86 | 1.676.104 | 154.070.671 | |
| 2019-12-26 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 142.812 | 10.995.279 | 1,32 | 13,72 | 1.959.381 | 150.855.228 | |
| 2019-11-18 |
|
4 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
P - Purchase | 1.470.588 | 14.636.334 | 11,17 | 3,40 | 4.999.999 | 49.763.536 | |
| 2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 333.800 | 11.919.925 | 2,88 | 1,74 | 580.812 | 20.740.670 | |
| 2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2.000.000 | 11.586.125 | 20,86 | 1,60 | 3.200.000 | 18.537.800 | |
| 2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 3.000.000 | 9.586.125 | 45,55 | 1,72 | 5.160.000 | 16.488.135 | |
| 2019-11-18 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 435.015 | 6.586.125 | 7,07 | 1,69 | 735.175 | 11.130.551 | |
| 2019-11-15 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
J - Other | -3.125.851 | 0 | -100,00 | ||||
| 2019-11-12 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.500.000 | 13.289.054 | 23,17 | 7,00 | 17.500.000 | 93.023.378 | |
| 2019-10-31 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -760.291 | 6.151.110 | -11,00 | 0,44 | -334.528 | 2.706.488 | |
| 2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -3.815.349 | 6.911.401 | -35,57 | 0,51 | -1.945.828 | 3.524.815 | |
| 2019-10-30 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
P - Purchase | 2.300.000 | 10.726.750 | 27,29 | 0,95 | 2.185.000 | 10.190.412 | |
| 2019-10-21 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50.000 | 10.852.467 | 0,46 | 10,93 | 546.500 | 118.617.464 | |
| 2019-10-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 67.222 | 10.802.467 | 0,63 | 10,29 | 691.714 | 111.157.385 | |
| 2019-09-24 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 20.000.000 | 45.951.556 | 77,07 | 0,50 | 10.000.000 | 22.975.778 | |
| 2019-09-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.735.245 | 0,28 | 13,58 | 407.400 | 145.784.627 | |
| 2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 56.416 | 10.705.245 | 0,53 | 14,27 | 805.056 | 152.763.846 | |
| 2019-09-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 13.584 | 10.648.829 | 0,13 | 14,05 | 190.855 | 149.616.047 | |
| 2019-08-20 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 425.531 | 6.433.277 | 7,08 | 23,50 | 9.999.978 | 151.182.010 | |
| 2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20.000 | 10.635.245 | 0,19 | 14,96 | 299.200 | 159.103.265 | |
| 2019-08-16 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.615.245 | 0,28 | 15,00 | 450.000 | 159.228.675 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 30.000 | 10.585.245 | 0,28 | 15,76 | 472.800 | 166.823.461 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 37.764 | 10.555.245 | 0,36 | 15,79 | 596.294 | 166.667.319 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 248.752 | 10.517.481 | 2,42 | 15,04 | 3.741.230 | 158.182.914 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 371.756 | 10.268.729 | 3,76 | 14,14 | 5.256.630 | 145.199.828 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 74.855 | 9.896.973 | 0,76 | 13,12 | 982.098 | 129.848.286 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 1.495 | 9.822.118 | 0,02 | 17,89 | 26.746 | 175.717.691 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 20.786 | 9.820.623 | 0,21 | 17,90 | 372.069 | 175.789.152 | |
| 2019-08-09 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 23.073 | 9.799.837 | 0,24 | 17,85 | 411.853 | 174.927.090 | |
| 2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
| 2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
| 2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
| 2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
| 2019-08-06 | 3 | FOMX |
Foamix Pharmaceuticals Ltd.
Common Stock |
22.407.762 | ||||||||
| 2019-07-29 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 2.822.581 | 6.749.803 | 71,87 | 4,65 | 13.125.002 | 31.386.584 | |
| 2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 42.916 | 3.708.705 | 1,17 | 16,67 | 715.410 | 61.824.112 | |
| 2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 12.354 | 3.665.789 | 0,34 | 16,89 | 208.659 | 61.915.176 | |
| 2019-07-11 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 29.834 | 3.653.435 | 0,82 | 16,61 | 495.543 | 60.683.555 | |
| 2019-07-09 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 50.000 | 3.632.601 | 1,40 | 16,46 | 823.000 | 59.792.612 | |
| 2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.705 | 3.573.601 | 0,05 | 16,67 | 28.422 | 59.571.929 | |
| 2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 715 | 3.571.896 | 0,02 | 16,14 | 11.540 | 57.650.401 | |
| 2019-07-03 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 18.121 | 3.571.181 | 0,51 | 14,24 | 258.043 | 50.853.617 | |
| 2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 39.383 | 3.553.060 | 1,12 | 14,48 | 570.266 | 51.448.309 | |
| 2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 60.617 | 3.513.560 | 1,76 | 13,97 | 846.819 | 49.084.433 | |
| 2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 186.696 | 3.453.060 | 5,72 | 13,58 | 2.535.332 | 46.892.555 | |
| 2019-07-01 |
|
4 | DOVA |
Dova Pharmaceuticals Inc.
Common Stock |
P - Purchase | 140.513 | 3.266.364 | 4,50 | 12,46 | 1.750.792 | 40.698.895 | |
| 2019-07-01 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1.000.000 | 4.210.542 | 31,15 | 3,00 | 3.000.000 | 12.631.626 | |
| 2019-06-20 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1.000.000 | 25.951.556 | 4,01 | 0,65 | 650.000 | 16.868.511 | |
| 2019-06-20 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 50.742 | 9.776.764 | 0,52 | 17,73 | 899.656 | 173.342.026 | |
| 2019-06-19 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 130.000 | 9.726.022 | 1,35 | 17,94 | 2.332.200 | 174.484.835 | |
| 2019-06-18 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 1.000.000 | 24.951.556 | 4,18 | 0,62 | 618.000 | 15.420.062 | |
| 2019-06-18 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 324.290 | 9.596.022 | 3,50 | 17,69 | 5.736.690 | 169.753.629 | |
| 2019-06-17 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 75.710 | 9.271.732 | 0,82 | 17,05 | 1.290.856 | 158.083.031 | |
| 2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Common Stock |
P - Purchase | 4.000.000 | 11.521.102 | 53,18 | 4,00 | 16.000.000 | 46.084.408 | |
| 2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 250.000 | 250.000 | |||||
| 2019-05-23 |
|
4 | ADMA |
ADMA BIOLOGICS, INC.
Warrants (right to buy) |
P - Purchase | 1.360.000 | 1.360.000 | |||||
| 2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
| 2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
| 2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
| 2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
| 2019-05-08 | 3 | ATNX |
Athenex, Inc.
Common Stock |
18.192.044 | ||||||||
| 2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 77.010 | 9.196.022 | 0,84 | 12,90 | 993.429 | 118.628.684 | |
| 2019-05-08 |
|
4 | ATNX |
Athenex, Inc.
Common Stock |
P - Purchase | 22.990 | 9.119.012 | 0,25 | 12,08 | 277.719 | 110.157.665 | |
| 2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
| 2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
| 2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
| 2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
| 2019-03-06 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
16.853.500 | ||||||||
| 2019-03-05 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.304.348 | 6.007.746 | 27,73 | 13,80 | 18.000.002 | 82.906.895 | |
| 2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 400.000 | 3.210.541 | 14,23 | 2,70 | 1.080.000 | 8.668.461 | |
| 2019-01-17 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 10.000 | 2.810.541 | 0,36 | 5,00 | 50.000 | 14.052.705 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -450.235 | 2.253.376 | -16,65 | 5,26 | -2.368.236 | 11.852.758 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -800.000 | 2.703.611 | -22,83 | 5,25 | -4.200.000 | 14.193.958 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25.800 | 3.503.611 | -0,73 | 6,46 | -166.668 | 22.633.327 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -25.800 | 3.503.611 | -0,73 | 6,46 | -166.668 | 22.633.327 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.200 | 3.529.411 | -0,12 | 5,26 | -22.092 | 18.564.702 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.200 | 3.529.411 | -0,12 | 5,26 | -22.092 | 18.564.702 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -4.592 | 3.563.611 | -0,13 | 9,52 | -43.716 | 33.925.577 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -34.401 | 3.568.203 | -0,95 | 9,05 | -311.329 | 32.292.237 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -131.866 | 3.602.604 | -3,53 | 7,56 | -996.907 | 27.235.686 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -147.497 | 3.734.470 | -3,80 | 6,67 | -983.805 | 24.908.915 | |
| 2019-01-09 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
S - Sale | -431.644 | 3.881.967 | -10,01 | 5,64 | -2.434.472 | 21.894.294 | |
| 2018-12-17 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 14.285.714 | 23.631.439 | 152,86 | 1,40 | 20.000.000 | 33.084.015 | |
| 2018-12-10 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 2.000.000 | 10.789.054 | 22,76 | 6,50 | 13.000.000 | 70.128.851 | |
| 2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -2.350.000 | 2.724.686 | -46,31 | 12,52 | -29.422.000 | 34.113.069 | |
| 2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500.000 | 5.074.686 | -8,97 | 12,51 | -6.255.000 | 63.484.322 | |
| 2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -500.000 | 5.574.686 | -8,23 | 12,50 | -6.250.000 | 69.683.575 | |
| 2018-10-15 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
S - Sale | -282.447 | 6.074.686 | -4,44 | 12,51 | -3.533.412 | 75.994.322 | |
| 2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 30.000 | 20.724.424 | 0,14 | 12,69 | 380.700 | 262.992.941 | |
| 2018-10-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 20.000 | 20.694.424 | 0,10 | 12,45 | 249.000 | 257.645.579 | |
| 2018-09-25 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50.000 | 20.674.424 | 0,24 | 12,53 | 626.500 | 259.050.533 | |
| 2018-09-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 20.624.424 | 0,49 | 11,74 | 1.174.000 | 242.130.738 | |
| 2018-09-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 500.000 | 20.524.424 | 2,50 | 12,00 | 6.001.500 | 246.354.661 | |
| 2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.186.205 | 0 | -100,00 | ||||
| 2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400.000 | 2.587.953 | 18,28 | 17,00 | 6.800.000 | 43.995.201 | |
| 2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.880.305 | 2.187.953 | 611,19 | ||||
| 2018-08-27 |
|
4/A | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 307.648 | 307.648 | 21,30 | 6.552.902 | 6.552.902 | ||
| 2018-08-14 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 100.000 | 4.070.357 | 2,52 | 52,00 | 5.200.000 | 211.658.564 | |
| 2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series C Preferred Stock |
C - Conversion | -2.193.463 | 0 | -100,00 | ||||
| 2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Series B Preferred Stock |
C - Conversion | -1.937.984 | 0 | -100,00 | ||||
| 2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
P - Purchase | 1.000.000 | 3.410.412 | 41,49 | 15,00 | 15.000.000 | 51.156.180 | |
| 2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1.279.733 | 2.410.412 | 113,18 | ||||
| 2018-08-01 |
|
4 | VRCA |
Verrica Pharmaceuticals Inc.
Common Stock |
C - Conversion | 1.130.679 | 1.130.679 | |||||
| 2018-07-26 |
|
4 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
S - Sale | -298.628 | 3.231.372 | -8,46 | 0,30 | -89.439 | 967.796 | |
| 2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Warrants (right to buy) |
X - Other | -2.306.034 | 0 | -100,00 | ||||
| 2018-07-20 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
X - Other | 2.306.034 | 8.789.054 | 35,57 | 5,80 | 13.374.997 | 50.976.513 | |
| 2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -6.186.205 | 0 | -100,00 | ||||
| 2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 400.000 | 2.280.305 | 21,27 | 17,00 | 6.800.000 | 38.765.185 | |
| 2018-07-20 |
|
4 | CRNX |
Crinetics Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.880.305 | 1.880.305 | |||||
| 2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
| 2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
| 2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
| 2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
| 2018-06-22 | 3 | KDMN |
Kadmon Holdings, Inc.
Common Stock |
26.331.492 | ||||||||
| 2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 5.591 | 3.125.851 | 0,18 | 29,82 | 166.724 | 93.212.877 | |
| 2018-06-13 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 14.109 | 3.120.260 | 0,45 | 29,18 | 411.701 | 91.049.187 | |
| 2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.000 | 3.106.151 | 0,06 | 28,97 | 57.940 | 89.985.194 | |
| 2018-06-12 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 23.000 | 3.104.151 | 0,75 | 28,62 | 658.260 | 88.840.802 | |
| 2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 1.333.333 | 4.703.398 | 39,56 | 15,00 | 19.999.995 | 70.550.970 | |
| 2018-06-12 |
|
4 | MGTX |
MeiraGTx Holdings plc
Ordinary Shares |
P - Purchase | 50.000 | 3.370.065 | 1,51 | 15,22 | 761.000 | 51.292.389 | |
| 2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 8.400 | 3.081.151 | 0,27 | 29,16 | 244.944 | 89.846.363 | |
| 2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 19.223 | 3.072.751 | 0,63 | 28,40 | 545.933 | 87.266.128 | |
| 2018-06-11 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 22.377 | 3.053.528 | 0,74 | 27,63 | 618.277 | 84.368.979 | |
| 2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 51.763 | 3.031.151 | 1,74 | 28,99 | 1.500.609 | 87.873.067 | |
| 2018-06-08 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 48.237 | 2.979.388 | 1,65 | 28,30 | 1.365.107 | 84.316.680 | |
| 2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
| 2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
| 2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
| 2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
| 2018-06-08 | 3 | MGTX |
MeiraGTx Holdings plc
Ordinary shares |
6.640.130 | ||||||||
| 2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 3.168 | 2.931.151 | 0,11 | 27,13 | 85.948 | 79.522.127 | |
| 2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 56.162 | 2.927.983 | 1,96 | 26,31 | 1.477.622 | 77.035.233 | |
| 2018-06-07 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 40.670 | 2.871.821 | 1,44 | 25,45 | 1.035.052 | 73.087.844 | |
| 2018-06-06 |
|
4 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 10.000 | 2.831.151 | 0,35 | 25,07 | 250.700 | 70.976.956 | |
| 2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
| 2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
| 2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
| 2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
| 2018-06-06 | 3 | DOVA |
Dova Pharmaceuticals, Inc.
Common Stock |
5.642.302 | ||||||||
| 2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 231.992 | 6.483.020 | 3,71 | 6,65 | 1.542.747 | 43.112.083 | |
| 2018-05-24 |
|
4 | QTNT |
Quotient Ltd
Ordinary Shares |
P - Purchase | 218.008 | 6.251.028 | 3,61 | 6,24 | 1.360.370 | 39.006.415 | |
| 2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
| 2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
| 2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
| 2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
| 2018-03-28 | 3 | AGRX |
AGILE THERAPEUTICS INC
Common Stock |
7.060.000 | ||||||||
| 2018-03-26 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 700.000 | 4.313.611 | 19,37 | 29,50 | 20.650.000 | 127.251.524 | |
| 2018-03-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 335.827 | 18.424.424 | 1,86 | 13,56 | 4.553.814 | 249.835.189 | |
| 2018-03-06 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 18.088.597 | 0,56 | 13,90 | 1.389.500 | 251.341.055 | |
| 2018-03-05 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 100.000 | 17.988.597 | 0,56 | 13,69 | 1.369.000 | 246.263.893 | |
| 2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -256.386 | 0 | -100,00 | ||||
| 2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
P - Purchase | 1.000.000 | 2.800.541 | 55,54 | 5,00 | 5.000.000 | 14.002.705 | |
| 2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
C - Conversion | 256.386 | 1.800.541 | 16,60 | ||||
| 2018-02-21 |
|
4 | MOTS |
Motus GI Holdings, Inc.
Warrant (right to buy) |
J - Other | 180.055 | 180.055 | |||||
| 2018-02-20 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 50.000 | 3.613.611 | 1,40 | 32,42 | 1.621.000 | 117.153.269 | |
| 2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 100.000 | 3.563.611 | 2,89 | 32,69 | 3.269.000 | 116.494.444 | |
| 2018-02-15 |
|
4 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
P - Purchase | 75.000 | 3.463.611 | 2,21 | 32,75 | 2.456.250 | 113.433.260 | |
| 2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
| 2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
| 2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
| 2018-02-13 | 3 | MOTS |
Motus GI Holdings, Inc.
Common Stock |
3.088.310 | ||||||||
| 2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 20.000 | 3.927.222 | 0,51 | 27,33 | 546.520 | 107.315.268 | |
| 2018-01-30 |
|
4 | SLDB |
Solid Biosciences Inc.
Common Stock |
P - Purchase | 1.000.000 | 3.907.222 | 34,40 | 16,00 | 16.000.000 | 62.515.552 | |
| 2018-01-25 |
|
4 | ALBO |
ALBIREO PHARMA, INC.
Common Stock |
P - Purchase | 275.000 | 1.595.000 | 20,83 | 33,00 | 9.075.000 | 52.635.000 | |
| 2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
| 2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
| 2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
| 2018-01-25 | 3 | SLDB |
Solid Biosciences, LLC
Common Stock |
5.814.444 | ||||||||
| 2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 310.000 | 6.357.133 | 5,13 | 12,80 | 3.968.000 | 81.371.302 | |
| 2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 149.650 | 6.047.133 | 2,54 | 12,24 | 1.831.716 | 74.016.908 | |
| 2018-01-18 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 50.350 | 5.897.483 | 0,86 | 11,83 | 595.640 | 69.767.224 | |
| 2017-12-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 175.000 | 4.889.066 | 3,71 | 38,00 | 6.650.000 | 185.784.508 | |
| 2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
| 2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
| 2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
| 2017-12-18 | 3 | LJPC |
LA JOLLA PHARMACEUTICAL CO
Common Stock |
6.777.222 | ||||||||
| 2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
| 2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
| 2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
| 2017-12-15 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
9.428.132 | ||||||||
| 2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
| 2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
| 2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
| 2017-12-04 | 3 | ALBO |
ALBIREO PHARMA, INC.
Common stock |
2.640.000 | ||||||||
| 2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
| 2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
| 2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
| 2017-11-15 | 3 | ADMA |
ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share |
7.642.204 | ||||||||
| 2017-11-01 | 3/A | QTNT |
Quotient Ltd
Ordinary Shares |
6.033.020 | ||||||||
| 2017-10-30 |
|
4 | VBIV |
VBI Vaccines Inc/BC
Common Stock |
P - Purchase | 3.100.000 | 9.345.725 | 49,63 | 3,05 | 9.455.000 | 28.504.461 | |
| 2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
| 2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
| 2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
| 2017-10-26 | 3 | QTNT |
Quotient Ltd
Ordinary Shares |
12.086.040 | ||||||||
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 22.055 | 3.670.357 | 0,60 | 27,67 | 610.341 | 101.571.991 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.920 | 3.648.302 | 0,25 | 40,14 | 358.081 | 146.455.976 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 12.586 | 3.639.382 | 0,35 | 39,22 | 493.600 | 142.730.011 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.112 | 3.626.796 | 0,22 | 38,56 | 312.791 | 139.845.990 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6.153 | 3.618.684 | 0,17 | 37,14 | 228.530 | 134.402.266 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 3.800 | 3.612.531 | 0,11 | 36,26 | 137.805 | 131.006.630 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 6.000 | 3.608.731 | 0,17 | 34,91 | 209.475 | 125.989.821 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 8.260 | 3.602.731 | 0,23 | 33,86 | 279.665 | 121.980.185 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 15.937 | 3.594.471 | 0,45 | 32,96 | 525.311 | 118.479.875 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 102.199 | 3.578.534 | 2,94 | 31,90 | 3.260.240 | 114.158.455 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 28.033 | 3.476.335 | 0,81 | 31,19 | 874.220 | 108.410.898 | |
| 2017-10-03 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 300.000 | 3.970.357 | 8,17 | 37,50 | 11.250.000 | 148.888.388 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -350.000 | 2.099.563 | -14,29 | 3,35 | -1.172.500 | 7.033.536 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -500.000 | 2.449.563 | -16,95 | 3,27 | -1.633.250 | 8.001.498 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250.000 | 2.949.563 | -7,81 | 3,17 | -792.500 | 9.350.115 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -250.000 | 3.199.563 | -7,25 | 3,03 | -757.250 | 9.691.476 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -300.000 | 3.449.563 | -8,00 | 3,09 | -926.250 | 10.650.526 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -353.421 | 3.749.563 | -8,61 | 3,56 | -1.258.143 | 13.348.069 | |
| 2017-09-25 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
S - Sale | -126.579 | 4.102.984 | -2,99 | 3,74 | -473.659 | 15.353.366 | |
| 2017-09-21 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 3.085.458 | 6,93 | 7,25 | 1.450.000 | 22.369.570 | |
| 2017-07-14 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 1.500.000 | 17.888.597 | 9,15 | 12,25 | 18.375.000 | 219.135.313 | |
| 2017-07-05 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 301.004 | 5.847.133 | 5,43 | 7,70 | 2.319.236 | 45.052.160 | |
| 2017-07-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 296.007 | 2.885.458 | 11,43 | 4,60 | 1.361.632 | 13.273.107 | |
| 2017-07-05 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 175.653 | 3.448.302 | 5,37 | 14,45 | 2.538.186 | 49.827.964 | |
| 2017-06-21 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -875.000 | 4.533.728 | -16,18 | 2,40 | -2.100.000 | 10.880.947 | |
| 2017-05-25 |
|
4 | CORI |
Corium International, Inc.
Common Stock |
P - Purchase | 1.902.400 | 5.546.129 | 52,21 | 6,25 | 11.890.000 | 34.663.306 | |
| 2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
| 2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
| 2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
| 2017-05-25 | 3 | CORI |
Corium International, Inc.
Common Stock |
7.287.458 | ||||||||
| 2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
| 2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
| 2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
| 2017-05-18 | 3 | ZGNX |
ZOGENIX, INC.
Common Stock |
6.545.298 | ||||||||
| 2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59.133 | 4.229.563 | 1,42 | 15,51 | 917.425 | 65.619.978 | |
| 2017-03-14 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34.883 | 4.170.430 | 0,84 | 14,94 | 521.281 | 62.321.655 | |
| 2017-02-15 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 893.025 | 2.589.451 | 52,64 | 4,50 | 4.018.612 | 11.652.530 | |
| 2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 59.133 | 4.228.563 | 1,42 | 15,51 | 917.425 | 65.604.464 | |
| 2017-02-14 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 34.883 | 4.169.430 | 0,84 | 14,94 | 521.281 | 62.306.711 | |
| 2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 41.211 | 4.134.547 | 1,01 | 14,27 | 587.928 | 58.984.688 | |
| 2017-02-10 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 104.612 | 4.093.336 | 2,62 | 13,51 | 1.413.319 | 55.301.379 | |
| 2017-01-04 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 94.750 | 4.013.411 | 2,42 | 14,66 | 1.388.846 | 58.828.578 | |
| 2017-01-04 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94.750 | 16.293.847 | 0,58 | 4,96 | 470.055 | 80.833.775 | |
| 2017-01-04 |
|
4/A | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 71.063 | 3.989.724 | 1,81 | 14,66 | 1.041.641 | 58.481.374 | |
| 2016-12-30 |
|
4 | VSAR |
Versartis, Inc.
Common Stock |
P - Purchase | 47.375 | 3.918.661 | 1,22 | 14,37 | 680.589 | 56.295.484 | |
| 2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 94.750 | 16.293.847 | 0,58 | 4,85 | 459.916 | 79.090.333 | |
| 2016-12-30 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47.375 | 16.199.097 | 0,29 | 4,91 | 232.706 | 79.569.964 | |
| 2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 37.900 | 16.151.722 | 0,24 | 4,92 | 186.582 | 79.514.927 | |
| 2016-12-27 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 47.375 | 16.113.822 | 0,29 | 4,72 | 223.468 | 76.008.898 | |
| 2016-12-23 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 189.500 | 16.066.447 | 1,19 | 4,51 | 854.834 | 72.475.742 | |
| 2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 1.341.282 | 2.068.824 | 184,36 | 3,36 | 4.500.001 | 6.940.905 | |
| 2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Warrant |
P - Purchase | 363.771 | 727.542 | 100,00 | 4,13 | 1.502.374 | 3.004.748 | |
| 2016-12-08 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 3.383.955 | 6.213.314 | 119,60 | 3,05 | 10.321.063 | 18.950.608 | |
| 2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
| 2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
| 2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
| 2016-12-02 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
26.447.894 | ||||||||
| 2016-12-02 | 3/A | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
15.876.947 | ||||||||
| 2016-10-05 | 3/A | VSAR |
Versartis, Inc.
Common Stock |
3.871.286 | ||||||||
| 2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -97.200 | 5.386.410 | -1,77 | 3,88 | -377.117 | 20.898.194 | |
| 2016-09-30 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -119.300 | 5.483.610 | -2,13 | 3,96 | -472.380 | 21.712.902 | |
| 2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
| 2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
| 2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
| 2016-09-28 | 3 | VSAR |
Versartis, Inc.
Common Stock |
7.594.838 | ||||||||
| 2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -115.923 | 5.602.910 | -2,03 | 3,63 | -420.511 | 20.324.556 | |
| 2016-09-16 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -276.927 | 5.718.833 | -4,62 | 3,73 | -1.032.301 | 21.318.094 | |
| 2016-08-26 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
S - Sale | -1.100.000 | 14.139.444 | -7,22 | 6,81 | -7.491.000 | 96.289.614 | |
| 2016-05-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 700.000 | 1.940.458 | 56,43 | 5,00 | 3.500.000 | 9.702.290 | |
| 2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -42.300 | 5.995.760 | -0,70 | 5,35 | -226.132 | 32.052.733 | |
| 2015-11-19 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -133.900 | 6.038.060 | -2,17 | 5,36 | -717.409 | 32.350.718 | |
| 2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -17.100 | 6.171.960 | -0,28 | 4,47 | -76.365 | 27.562.739 | |
| 2015-11-09 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -75.000 | 6.189.060 | -1,20 | 4,62 | -346.260 | 28.573.652 | |
| 2015-11-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 45.100 | 1.240.458 | 3,77 | 6,50 | 293.150 | 8.062.977 | |
| 2015-10-28 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 50.000 | 1.195.358 | 4,37 | 6,46 | 323.150 | 7.725.599 | |
| 2015-10-26 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 18.020 | 1.145.358 | 1,60 | 6,47 | 116.661 | 7.415.048 | |
| 2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 22.797 | 1.127.338 | 2,06 | 6,44 | 146.858 | 7.262.311 | |
| 2015-10-22 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
P - Purchase | 14.348 | 1.104.541 | 1,32 | 6,30 | 90.335 | 6.954.190 | |
| 2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
| 2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
| 2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
| 2015-10-22 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
2.180.386 | ||||||||
| 2015-10-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 50.000 | 15.239.444 | 0,33 | 6,27 | 313.500 | 95.551.314 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 7.000 | 15.189.444 | 0,05 | 6,34 | 44.380 | 96.301.075 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14.000 | 15.182.444 | 0,09 | 6,47 | 90.580 | 98.230.413 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 14.000 | 15.168.444 | 0,09 | 6,65 | 93.100 | 100.870.153 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 43.000 | 15.154.444 | 0,28 | 6,34 | 272.620 | 96.079.175 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86.000 | 15.111 | -121,32 | 6,47 | 556.420 | 97.771 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 86.000 | 15.025.444 | 0,58 | 6,65 | 571.900 | 99.919.203 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35.000 | 14.939.444 | 0,23 | 6,76 | 236.600 | 100.990.641 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 35.000 | 14.904.444 | 0,24 | 6,85 | 239.750 | 102.095.441 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215.000 | 14.869.444 | 1,47 | 6,76 | 1.453.400 | 100.517.441 | |
| 2015-10-07 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 215.000 | 14.654.444 | 1,49 | 6,85 | 1.472.750 | 100.382.941 | |
| 2015-09-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
S - Sale | -310.000 | 6.264.060 | -4,72 | 4,18 | -1.294.777 | 26.163.099 | |
| 2015-08-18 |
|
4 | VBIV |
VBI VACCINES INC.
Common Stock |
P - Purchase | 650.000 | 3.260.356 | 24,90 | 2,08 | 1.352.000 | 6.781.540 | |
| 2014-11-19 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 2.100.000 | 14.439.444 | 17,02 | 6,50 | 13.650.000 | 93.856.386 | |
| 2014-08-04 | 3 | VBIV |
VBI VACCINES INC.
Common Stock |
4.540.808 | ||||||||
| 2014-08-04 | 3 | VBIV |
VBI VACCINES INC.
Common Stock |
4.540.808 | ||||||||
| 2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 530.000 | 12.339.444 | 4,49 | 3,50 | 1.855.000 | 43.188.054 | |
| 2014-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
P - Purchase | 3.470.000 | 11.809.444 | 41,61 | 3,50 | 12.145.000 | 41.333.054 | |
| 2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
| 2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
| 2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
| 2014-05-30 | 3 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
16.678.888 | ||||||||
| 2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.500 | 6.574.060 | 0,10 | 6,50 | 42.238 | 42.718.899 | |
| 2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93.500 | 6.567.560 | 1,44 | 6,50 | 607.572 | 42.676.662 | |
| 2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.500 | 6.474.060 | 0,10 | 6,52 | 42.358 | 42.188.859 | |
| 2013-11-12 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 93.500 | 6.467.560 | 1,47 | 6,52 | 609.302 | 42.146.501 | |
| 2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.250 | 6.374.060 | 0,05 | 6,84 | 22.220 | 43.579.448 | |
| 2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 46.750 | 6.370.810 | 0,74 | 6,84 | 319.630 | 43.557.228 | |
| 2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.825 | 6.324.060 | 0,11 | 6,88 | 46.959 | 43.512.062 | |
| 2013-11-06 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 98.175 | 6.317.235 | 1,58 | 6,88 | 675.483 | 43.465.104 | |
| 2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 150.218 | 6.219.060 | 2,48 | 7,17 | 1.077.033 | 44.589.416 | |
| 2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 10.442 | 6.068.842 | 0,17 | 7,17 | 74.867 | 43.512.383 | |
| 2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.000 | 6.058.400 | 0,13 | 6,69 | 53.546 | 40.550.083 | |
| 2013-11-04 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 192.000 | 6.050.400 | 3,28 | 6,69 | 1.285.094 | 40.496.537 | |
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -50.000 | 2.823.426 | -1,74 | 89,20 | -4.460.000 | 251.849.599 | |
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
S - Sale | -700.000 | 2.873.426 | -19,59 | 89,20 | -62.440.000 | 256.309.599 | |
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1.000 | 0 | -100,00 | ||||
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
X - Other | -1.000 | 0 | -100,00 | ||||
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100.000 | 3.573.426 | 2,88 | 25,00 | 2.500.000 | 89.335.650 | |
| 2013-09-09 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
X - Other | 100.000 | 3.473.426 | 2,96 | 25,00 | 2.500.000 | 86.835.650 | |
| 2013-07-24 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 850.000 | 5.858.400 | 16,97 | 11,65 | 9.902.500 | 68.250.360 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.000 | 2,33 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.000 | 2,33 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 22.500 | 2,27 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23.000 | 2,22 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 500 | 23.500 | 2,17 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 24.000 | 4,35 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 24.000 | 4,35 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 25.000 | 4,17 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.500 | 26.000 | 6,12 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2.000 | 27.500 | 7,84 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 2.000 | 27.500 | 7,84 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 6.000 | 29.500 | 25,53 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 1.000 | 36.000 | 2,86 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to sell) |
E - Other | 4.000 | 40.000 | 11,11 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.000 | 1,15 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.000 | 1,15 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 44.500 | 1,14 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | 45.000 | 1,12 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 45.500 | 2,25 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 45.500 | 2,25 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 500 | ||||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 47.500 | 2,15 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 48.500 | 2,11 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.500 | 49.500 | 3,12 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.500 | 49.500 | 3,12 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4.000 | 51.000 | 8,51 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 4.000 | 51.000 | 8,51 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 1.000 | 55.000 | 1,85 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
X - Other | 2.000 | 56.000 | 3,70 | ||||
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 812.560 | -5,80 | 10,00 | -500.000 | 8.125.600 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 812.560 | -5,80 | 10,00 | -500.000 | 8.125.600 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -50.000 | 862.560 | -5,48 | 12,50 | -625.000 | 10.782.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 962.560 | -9,41 | 12,50 | -1.250.000 | 12.032.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 1.162.560 | -7,92 | 10,00 | -1.000.000 | 11.625.600 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150.000 | 1.362.560 | -9,92 | 12,50 | -1.875.000 | 17.032.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400.000 | 1.512.560 | -20,91 | 12,50 | -5.000.000 | 18.907.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -400.000 | 1.512.560 | -20,91 | 12,50 | -5.000.000 | 18.907.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -200.000 | 2.012.560 | -9,04 | 12,50 | -2.500.000 | 25.157.000 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -150.000 | 2.612.560 | -5,43 | 15,00 | -2.250.000 | 39.188.400 | |
| 2013-03-20 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
X - Other | -100.000 | 2.762.560 | -3,49 | 10,00 | -1.000.000 | 27.625.600 | |
| 2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 64.500 | 0,78 | 2,76 | 1.380 | 178.020 | |
| 2013-03-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 64.000 | 1,59 | 1,94 | 1.945 | 124.480 | |
| 2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1.000 | 2.000 | 100,00 | 8,26 | 8.260 | 16.520 | |
| 2013-03-06 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Call option (right to buy) |
P - Purchase | 1.000 | 2.000 | 100,00 | 8,26 | 8.260 | 16.520 | |
| 2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 63.000 | 0,80 | 0,90 | 450 | 56.700 | |
| 2013-02-27 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 62.500 | -0,79 | 1,05 | -525 | 65.625 | |
| 2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 500 | 62.000 | 0,81 | 0,78 | 390 | 48.360 | |
| 2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 61.500 | -0,81 | 1,04 | -520 | 63.960 | |
| 2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 61.000 | 1,67 | 0,79 | 790 | 48.190 | |
| 2013-02-21 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 60.000 | -1,64 | 0,89 | -890 | 53.400 | |
| 2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 59.000 | 1,72 | 2,08 | 2.080 | 122.720 | |
| 2013-02-13 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 58.000 | -1,69 | 0,38 | -380 | 22.040 | |
| 2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.500 | 57.000 | 2,70 | 2,33 | 3.495 | 132.810 | |
| 2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.500 | 55.500 | -2,63 | 0,27 | -405 | 14.985 | |
| 2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4.000 | 54.000 | 8,00 | 1,65 | 6.600 | 89.100 | |
| 2013-02-08 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 50.000 | -3,85 | 0,55 | -1.100 | 27.500 | |
| 2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -6.000 | 48.000 | -11,11 | 0,69 | -4.140 | 33.120 | |
| 2013-02-06 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 42.000 | -1,18 | 2,05 | -1.025 | 86.100 | |
| 2013-02-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50.000 | 3.373.426 | 1,50 | 27,79 | 1.389.400 | 93.740.762 | |
| 2013-02-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 41.500 | -2,35 | 0,80 | -800 | 33.200 | |
| 2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 40.500 | 2,53 | 1,45 | 1.450 | 58.725 | |
| 2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 39.500 | -2,47 | 0,88 | -875 | 34.562 | |
| 2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 38.500 | 5,48 | 1,32 | 2.650 | 51.012 | |
| 2013-02-01 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 36.500 | -5,19 | 1,05 | -2.100 | 38.325 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 4.000 | 34.500 | 13,11 | 1,71 | 6.840 | 58.995 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30.500 | 1,67 | 0,05 | 25 | 1.525 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (right to buy) |
P - Purchase | 500 | 30.000 | 1,69 | 0,10 | 50 | 3.000 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -4.000 | 29.500 | -11,94 | 0,80 | -3.200 | 23.600 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 25.500 | 8,51 | 1,50 | 3.000 | 38.250 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 23.500 | 9,30 | 1,85 | 3.700 | 43.475 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 2.000 | 21.500 | 10,26 | 0,65 | 1.300 | 13.979 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.500 | 19.500 | 8,33 | 2,87 | 4.300 | 55.901 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Put option (right to sell) |
P - Purchase | 1.000 | 18.000 | 5,88 | 0,80 | 800 | 14.400 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 17.000 | -5,56 | 1,19 | -1.190 | 20.230 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 16.000 | -5,88 | 2,43 | -2.428 | 38.846 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 15.000 | -6,25 | 0,80 | -800 | 12.000 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 14.000 | -12,50 | 1,47 | -2.935 | 20.545 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 12.000 | -14,29 | 1,00 | -2.001 | 12.004 | |
| 2013-01-30 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 10.000 | -16,67 | 0,88 | -1.757 | 8.787 | |
| 2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 8.000 | -5,88 | 0,80 | -400 | 6.400 | |
| 2013-01-23 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -500 | 7.500 | -6,25 | 1,40 | -702 | 10.531 | |
| 2013-01-22 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50.000 | 3.323.426 | 1,53 | 27,62 | 1.381.000 | 91.793.026 | |
| 2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25.000 | 3.273.426 | 0,77 | 26,73 | 668.142 | 87.484.601 | |
| 2013-01-18 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25.000 | 3.273.426 | 0,77 | 26,73 | 668.142 | 87.484.601 | |
| 2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 150.000 | 3.223.426 | 4,88 | 26,64 | 3.996.000 | 85.872.069 | |
| 2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 200.000 | 3.073.426 | 6,96 | 27,66 | 5.531.220 | 84.998.977 | |
| 2013-01-15 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 125.000 | 2.873.426 | 4,55 | 26,64 | 3.330.000 | 76.548.069 | |
| 2013-01-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 7.000 | -22,22 | 1,89 | -3.780 | 13.230 | |
| 2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 5.000 | -16,67 | 1,20 | -1.200 | 6.000 | |
| 2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 4.000 | -20,00 | 1,91 | -1.910 | 7.640 | |
| 2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -2.000 | 3.000 | -40,00 | 1,35 | -2.700 | 4.050 | |
| 2013-01-04 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Call option (obligation to sell) |
S - Sale | -1.000 | 1.000 | -50,00 | 2,01 | -2.010 | 2.010 | |
| 2012-12-13 | 3 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
5.008.400 | ||||||||
| 2012-12-05 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 20.000 | 2.615.293 | 0,77 | 21,27 | 425.400 | 55.627.282 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 70.000 | 2.565.293 | 2,81 | 21,76 | 1.523.200 | 55.820.776 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20.000 | 2.495.293 | 0,81 | 20,75 | 415.000 | 51.777.330 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 20.000 | 2.475.293 | 0,81 | 21,01 | 420.200 | 52.005.906 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 10.000 | 2.455.293 | 0,41 | 19,50 | 195.000 | 47.878.214 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30.000 | 2.445.293 | 1,24 | 21,12 | 633.600 | 51.644.588 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
P - Purchase | 30.000 | 2.595.293 | 1,17 | 22,71 | 681.300 | 58.939.104 | |
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
CALL OPTION (OBLIGATION TO SELL) |
X - Other | -2.475 | 0 | -100,00 | ||||
| 2012-12-03 |
|
4 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
X - Other | -247.500 | 2.347.233 | -9,54 | 17,50 | -4.331.250 | 41.076.578 | |
| 2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2.415.293 | ||||||||
| 2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133.133 | ||||||||
| 2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
2.594.733 | ||||||||
| 2012-12-03 | 3 | AEGR |
Aegerion Pharmaceuticals, Inc.
COMMON STOCK |
133.133 | ||||||||
| 2012-05-15 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 59.500 | 2.862.560 | 2,12 | 7,38 | 439.283 | 21.133.994 | |
| 2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 25.000 | 2.803.060 | 0,90 | 6,35 | 158.800 | 17.805.037 | |
| 2012-05-14 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 145.000 | 2.778.060 | 5,51 | 6,35 | 921.040 | 17.646.237 | |
| 2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 15.000 | 2.633.060 | 0,57 | 4,82 | 72.300 | 12.691.349 | |
| 2012-05-11 |
|
4 | RPRX |
REPROS THERAPEUTICS INC.
Common Stock |
P - Purchase | 310.000 | 2.618.060 | 13,43 | 4,82 | 1.493.797 | 12.615.646 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -9.600.000 | 20.580.260 | -31,81 | 0,15 | -1.466.880 | 3.144.664 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -299.570 | 0 | -100,00 | 0,15 | -45.774 | ||
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400.000 | 299.570 | -57,18 | 0,15 | -61.120 | 45.774 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -1.943.250 | 699.570 | -73,53 | 0,14 | -273.804 | 98.569 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -400.000 | 2.642.820 | -13,15 | 0,16 | -64.560 | 426.551 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -29.740 | 3.042.820 | -0,97 | 0,16 | -4.729 | 483.808 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -2.696.450 | 30.180.260 | -8,20 | 0,15 | -412.018 | 4.611.544 | |
| 2008-12-03 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
S - Sale | -24.681.360 | 32.876.710 | -42,88 | 0,14 | -3.477.604 | 4.632.328 | |
| 2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.040 | 3.072.560 | 0,07 | 3,23 | 6.589 | 9.924.369 | |
| 2008-06-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.960 | 57.558.070 | 0,09 | 3,23 | 158.141 | 185.912.566 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.340 | 3.070.520 | 0,04 | 3,36 | 4.502 | 10.316.947 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 32.260 | 57.509.110 | 0,06 | 3,36 | 108.394 | 193.230.610 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.000 | 3.069.180 | 0,13 | 3,43 | 13.720 | 10.527.287 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 96.000 | 57.476.850 | 0,17 | 3,43 | 329.280 | 197.145.596 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8.000 | 3.065.180 | 0,26 | 3,15 | 25.200 | 9.655.317 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.000 | 3.057.180 | 0,13 | 3,37 | 13.480 | 10.302.697 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 192.000 | 57.380.850 | 0,34 | 3,15 | 604.800 | 180.749.678 | |
| 2008-06-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinarry Shares |
P - Purchase | 96.000 | 57.188.850 | 0,17 | 3,37 | 323.520 | 192.726.424 | |
| 2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.000 | 3.036.140 | 0,07 | 3,88 | 7.760 | 11.780.223 | |
| 2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.000 | 56.683.890 | 0,08 | 3,88 | 186.240 | 219.933.493 | |
| 2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 4.200 | 3.034.140 | 0,14 | 3,75 | 15.750 | 11.378.025 | |
| 2008-05-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100.800 | 56.635.890 | 0,18 | 3,75 | 378.000 | 212.384.588 | |
| 2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 10.000 | 3.015.650 | 0,33 | 3,56 | 35.579 | 10.729.381 | |
| 2008-04-16 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 90.000 | 56.191.770 | 0,16 | 3,58 | 322.011 | 201.048.534 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.650 | 2.984.350 | 0,22 | 3,12 | 20.749 | 9.311.769 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 156.350 | 55.797.070 | 0,28 | 3,12 | 487.843 | 174.098.018 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.977.700 | 0,40 | 3,32 | 39.856 | 9.889.835 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.780 | 2.965.700 | 0,53 | 3,33 | 52.566 | 9.879.340 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 188.000 | 55.640.720 | 0,34 | 3,32 | 624.404 | 184.799.523 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 247.220 | 55.452.720 | 0,45 | 3,33 | 823.539 | 184.724.101 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.949.920 | 0,20 | 3,37 | 20.240 | 9.950.965 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 8.820 | 2.943.920 | 0,30 | 3,38 | 29.814 | 9.951.333 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.000 | 2.935.100 | 0,31 | 3,37 | 30.295 | 9.879.840 | |
| 2008-03-20 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 17.400 | 2.926.100 | 0,60 | 3,35 | 58.292 | 9.802.728 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 55.205.500 | 0,17 | 3,37 | 317.090 | 186.224.713 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 138.180 | 55.111.500 | 0,25 | 3,38 | 467.090 | 186.293.403 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 272.600 | 54.973.320 | 0,50 | 3,35 | 913.237 | 184.166.119 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141.000 | 54.700.720 | 0,26 | 3,37 | 474.620 | 184.128.094 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.900 | 2.908.700 | 0,41 | 3,30 | 39.327 | 9.612.672 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.896.800 | 1,05 | 3,31 | 99.351 | 9.593.333 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 107.100 | 54.559.720 | 0,20 | 3,30 | 353.944 | 180.308.963 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 54.452.620 | 0,87 | 3,31 | 1.556.499 | 180.330.742 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 25.200 | 2.866.800 | 0,89 | 3,28 | 82.568 | 9.393.070 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.841.600 | 1,07 | 3,15 | 94.500 | 8.951.040 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.811.600 | 1,08 | 3,25 | 97.368 | 9.125.329 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 394.800 | 5.398.260 | 7,89 | 3,28 | 1.293.562 | 17.687.399 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 53.587.820 | 0,88 | 3,15 | 1.480.500 | 168.801.633 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 53.117.820 | 0,89 | 3,25 | 1.525.432 | 172.399.197 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 60.000 | 2.781.600 | 2,20 | 3,74 | 224.268 | 10.397.064 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.020 | 2.721.600 | 0,33 | 3,65 | 32.893 | 9.924.859 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 141.440 | 52.647.820 | 0,27 | 3,65 | 515.789 | 191.990.805 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 940.000 | 52.506.380 | 1,82 | 3,74 | 3.513.532 | 196.258.347 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 39.300 | 2.712.580 | 1,47 | 3,86 | 151.824 | 10.479.239 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.600 | 2.673.280 | 0,59 | 3,73 | 58.146 | 9.964.117 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 244.400 | 51.566.380 | 0,48 | 3,73 | 910.952 | 192.203.368 | |
| 2008-03-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 615.700 | 51.321.980 | 1,21 | 3,86 | 2.378.572 | 198.267.073 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 34.200 | 2.657.680 | 1,30 | 3,94 | 134.700 | 10.467.538 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 535.800 | 50.706.280 | 1,07 | 3,94 | 2.110.302 | 199.711.754 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.640 | 2.623.480 | 0,25 | 3,99 | 26.490 | 10.466.111 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 2.616.840 | 0,69 | 3,98 | 71.656 | 10.417.378 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 50.170.480 | 0,57 | 3,98 | 1.122.614 | 199.723.664 | |
| 2008-03-10 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 104.060 | 49.888.480 | 0,21 | 3,99 | 415.137 | 199.025.102 | |
| 2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.600 | 2.598.840 | 0,25 | 4,01 | 26.484 | 10.428.365 | |
| 2008-02-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 103.400 | 49.784.420 | 0,21 | 4,01 | 414.913 | 199.769.942 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 3.790 | 2.592.240 | 0,15 | 3,95 | 14.970 | 10.239.348 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24.000 | 2.588.450 | 0,94 | 3,91 | 93.742 | 10.110.227 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 59.390 | 49.681.020 | 0,12 | 3,95 | 234.590 | 196.240.029 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376.000 | 49.621.630 | 0,76 | 3,91 | 1.468.618 | 193.817.125 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 46.500 | 2.564.450 | 1,85 | 3,87 | 179.871 | 9.919.805 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.517.950 | 0,24 | 3,86 | 23.159 | 9.718.783 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 49.245.630 | 0,19 | 3,86 | 362.821 | 190.078.283 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 728.500 | 49.151.630 | 1,50 | 3,87 | 2.817.984 | 190.128.335 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.511.950 | 0,48 | 3,95 | 47.431 | 9.928.734 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.499.950 | 1,21 | 3,95 | 118.374 | 9.864.303 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28.380 | 2.469.950 | 1,16 | 3,95 | 112.101 | 9.756.302 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188.000 | 48.432.130 | 0,39 | 3,95 | 743.089 | 191.432.837 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 48.235.130 | 0,98 | 3,95 | 1.854.526 | 190.326.176 | |
| 2008-02-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 444.620 | 47.765.130 | 0,94 | 3,95 | 1.756.249 | 188.672.264 | |
| 2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 100 | 2.441.570 | 0,00 | 3,84 | 384 | 9.375.629 | |
| 2008-02-22 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 900 | 47.320.510 | 0,00 | 3,84 | 3.456 | 181.710.758 | |
| 2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 360 | 2.441.470 | 0,01 | 3,81 | 1.371 | 9.297.606 | |
| 2008-02-19 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 5.640 | 473.196.910 | 0,00 | 3,81 | 21.478 | 1.802.028.473 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 600 | 3.441.110 | 0,02 | 3,40 | 2.038 | 11.686.010 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9.400 | 47.313.970 | 0,02 | 3,40 | 31.922 | 160.678.242 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 21.000 | 2.440.510 | 0,87 | 3,71 | 77.914 | 9.054.780 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 120 | 2.419.510 | 0,00 | 3,68 | 442 | 8.903.797 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 329.000 | 47.304.570 | 0,70 | 3,71 | 1.220.656 | 175.509.416 | |
| 2008-02-08 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 1.880 | 46.975.570 | 0,00 | 3,68 | 6.918 | 172.870.098 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 9.060 | 2.419.390 | 0,38 | 3,79 | 34.314 | 9.163.198 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 6.060 | 2.410.330 | 0,25 | 3,75 | 22.725 | 9.038.738 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 141.940 | 46.973.690 | 0,30 | 3,79 | 537.584 | 177.908.154 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 94.940 | 46.831.750 | 0,20 | 3,75 | 356.025 | 175.619.062 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 8.400 | 2.404.270 | 0,35 | 3,87 | 32.495 | 9.300.678 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 33.000 | 2.320.270 | 1,44 | 3,88 | 128.056 | 9.003.808 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 131.600 | 46.736.810 | 0,28 | 3,87 | 509.081 | 180.796.676 | |
| 2008-02-06 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary shares |
P - Purchase | 517.000 | 46.605.210 | 1,12 | 3,88 | 2.006.218 | 180.851.517 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.322.870 | 1,84 | 3,69 | 155.022 | 8.573.713 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 46.088.210 | 1,45 | 3,69 | 2.428.678 | 170.111.583 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 2.320.870 | 1,31 | 3,43 | 102.987 | 7.967.315 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 23.640 | 2.290.870 | 1,04 | 3,50 | 82.723 | 8.016.441 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 45.430.210 | 1,05 | 3,43 | 1.613.463 | 155.957.368 | |
| 2008-02-05 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 370.360 | 44.960.210 | 0,83 | 3,50 | 1.296.001 | 157.329.263 | |
| 2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.267.230 | 0,67 | 3,23 | 48.456 | 7.324.060 | |
| 2008-02-01 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 44.589.850 | 0,53 | 3,23 | 759.144 | 144.043.051 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 2.252.230 | 0,27 | 3,23 | 19.379 | 7.274.252 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 44.354.850 | 0,21 | 3,23 | 303.601 | 143.257.295 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 600 | 2.246.230 | 0,03 | 3,23 | 1.938 | 7.255.323 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 40.200 | 2.245.630 | 1,82 | 3,21 | 129.203 | 7.217.455 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.400 | 44.260.850 | 0,02 | 3,23 | 30.362 | 142.962.546 | |
| 2008-01-30 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 629.800 | 44.251.450 | 1,44 | 3,21 | 2.024.177 | 142.224.160 | |
| 2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.000 | 2.205.430 | 0,55 | 3,24 | 38.856 | 7.141.182 | |
| 2008-01-29 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 188.000 | 43.621.650 | 0,43 | 3,24 | 608.744 | 141.246.903 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.300 | 2.193.430 | 1,97 | 2,99 | 126.477 | 6.558.356 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 13.800 | 2.151.130 | 0,65 | 2,98 | 41.124 | 6.410.367 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 66.270 | 43.433.650 | 0,15 | 2,99 | 198.147 | 129.866.614 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 216.200 | 42.770.950 | 0,51 | 2,98 | 644.276 | 127.457.431 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 2.137.330 | 0,85 | 2,88 | 51.908 | 6.163.632 | |
| 2008-01-28 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 42.554.750 | 0,67 | 2,88 | 813.232 | 122.719.388 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 790 | 2.119.330 | 0,04 | 2,90 | 2.293 | 6.151.355 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 12.520 | 42.272.750 | 0,03 | 2,90 | 36.339 | 122.696.657 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 7.560 | 2.118.540 | 0,36 | 3,16 | 23.888 | 6.694.163 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.820 | 2.110.980 | 0,56 | 3,13 | 36.994 | 6.606.945 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 118.440 | 42.260.230 | 0,28 | 3,16 | 374.247 | 133.533.875 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 185.180 | 42.141.790 | 0,44 | 3,13 | 579.576 | 131.895.374 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 11.460 | 2.099.160 | 0,55 | 3,01 | 34.444 | 6.309.235 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 9.240 | 2.087.700 | 0,44 | 3,06 | 28.240 | 6.380.638 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 144.760 | 41.956.610 | 0,35 | 3,06 | 442.430 | 128.231.987 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 179.540 | 41.811.850 | 0,43 | 3,01 | 539.625 | 125.669.696 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27.600 | 2.078.460 | 1,35 | 3,06 | 84.346 | 6.351.774 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2.008.860 | 0,01 | 3,16 | 568 | 6.341.368 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432.400 | 41.632.310 | 1,05 | 3,10 | 1.340.440 | 129.060.161 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.820 | 41.199.910 | 0,01 | 3,16 | 8.902 | 130.055.756 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.050.680 | 2,09 | 3,11 | 130.712 | 6.382.126 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.008.680 | 0,75 | 3,06 | 45.909 | 6.147.766 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 41.197.090 | 1,62 | 3,11 | 2.047.828 | 128.213.583 | |
| 2008-01-25 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 40.539.090 | 0,58 | 3,06 | 719.241 | 124.073.939 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 27.600 | 2.078.460 | 1,35 | 3,10 | 85.560 | 6.443.226 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180 | 2.050.860 | 0,01 | 3,16 | 568 | 6.473.950 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 432.400 | 41.632.310 | 1,05 | 3,10 | 1.340.440 | 129.060.161 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 2.820 | 41.199.910 | 0,01 | 3,16 | 8.902 | 130.055.756 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 42.000 | 2.050.680 | 2,09 | 3,11 | 130.712 | 6.382.126 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 15.000 | 2.008.680 | 0,75 | 3,06 | 45.909 | 6.147.766 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 658.000 | 41.197.090 | 1,62 | 3,11 | 2.047.828 | 128.213.583 | |
| 2008-01-18 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 235.000 | 40.539.000 | 0,58 | 3,06 | 719.241 | 124.073.663 | |
| 2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 22.200 | 1.993.680 | 1,13 | 3,41 | 75.724 | 6.800.442 | |
| 2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 347.800 | 40.304.090 | 0,87 | 3,41 | 1.186.346 | 137.477.251 | |
| 2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 28.320 | 1.971.480 | 1,46 | 3,39 | 96.076 | 6.688.246 | |
| 2008-01-15 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 443.680 | 39.956.290 | 1,12 | 3,39 | 1.505.184 | 135.551.714 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69.000 | 1.943.160 | 3,68 | 3,30 | 227.748 | 6.413.788 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.081.000 | 39.521.610 | 2,81 | 3,30 | 3.568.057 | 130.448.978 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 36.000 | 1.874.160 | 1,96 | 3,27 | 117.896 | 6.137.687 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 24.060 | 1.838.160 | 1,33 | 3,30 | 79.283 | 6.057.105 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 564.000 | 37.431.610 | 1,53 | 3,27 | 1.847.044 | 122.584.780 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 376.940 | 37.867.610 | 1,01 | 3,30 | 1.242.093 | 124.781.348 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 30.000 | 1.814.100 | 1,68 | 3,26 | 97.743 | 5.910.519 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 20.000 | 1.784.100 | 1,13 | 2,87 | 57.372 | 5.117.869 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 81.600 | 1.764.100 | 4,85 | 3,11 | 253.401 | 5.478.236 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 6.000 | 1.682.500 | 0,36 | 3,10 | 18.600 | 5.215.750 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.278.400 | 37.020.670 | 3,58 | 3,11 | 3.969.943 | 114.963.989 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 94.000 | 35.742.270 | 0,26 | 3,10 | 291.400 | 110.801.037 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 180.000 | 35.648.270 | 0,51 | 2,87 | 516.348 | 102.260.627 | |
| 2008-01-11 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 470.000 | 37.490.670 | 1,27 | 3,26 | 1.531.307 | 122.148.352 | |
| 2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.222.000 | 35.045.270 | 3,61 | 2,89 | 3.531.580 | 101.280.830 | |
| 2008-01-04 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 78.000 | 1.649.500 | 4,96 | 2,89 | 225.420 | 4.767.055 | |
| 2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 69.000 | 1.571.500 | 4,59 | 2,74 | 188.750 | 4.298.838 | |
| 2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 1.081.000 | 33.823.270 | 3,30 | 2,74 | 2.957.076 | 92.523.555 | |
| 2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 48.000 | 1.502.500 | 3,30 | 2,69 | 129.226 | 4.045.030 | |
| 2008-01-02 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 752.000 | 32.742.270 | 2,35 | 2,69 | 2.024.534 | 88.148.739 | |
| 2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 18.000 | 1.454.500 | 1,25 | 2,60 | 46.717 | 3.775.009 | |
| 2007-12-31 |
|
4 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
P - Purchase | 282.000 | 31.990.270 | 0,89 | 2,60 | 731.903 | 83.027.547 | |
| 2007-12-31 | 3/A | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
31.708.270 | ||||||||
| 2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
27.876.060 | ||||||||
| 2007-12-07 | 3 | XTLB |
XTL BIOPHARMACEUTICALS LTD
Ordinary Shares |
1.436.500 | ||||||||
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.315.000 | 209.100 | -86,28 | 4,72 | -6.200.225 | 985.906 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -50.000 | 1.524.100 | -3,18 | 4,55 | -227.500 | 6.934.655 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -30.000 | 1.574.100 | -1,87 | 4,35 | -130.500 | 6.847.335 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -273.550 | 1.604.100 | -14,57 | 4,47 | -1.222.221 | 7.167.119 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.000 | 1.877.650 | 0,11 | 3,98 | 7.960 | 7.473.047 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -2.000 | 1.875.650 | -0,11 | 4,47 | -8.936 | 8.380.404 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -25.000 | 1.877.650 | -1,31 | 4,90 | -122.500 | 9.200.485 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -70.900 | 1.902.650 | -3,59 | 4,47 | -316.781 | 8.501.040 | |
| 2004-12-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -28.550 | 0 | -100,00 | 4,47 | -127.561 | ||
| 2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 14.900 | 1.973.550 | 0,76 | 9,87 | 146.991 | 19.469.465 | |
| 2004-10-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 27.950 | 3,71 | 9,87 | 9.865 | 275.732 | |
| 2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.958.650 | 0,46 | 10,11 | 90.964 | 19.796.271 | |
| 2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 26.950 | 3,85 | 10,11 | 10.107 | 272.386 | |
| 2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.949.650 | 0,46 | 9,90 | 89.112 | 19.304.070 | |
| 2004-10-08 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 25.950 | 4,01 | 9,90 | 9.901 | 256.939 | |
| 2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 15.800 | 1.940.650 | 0,82 | 9,90 | 156.417 | 19.212.047 | |
| 2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.700 | 24.950 | 7,31 | 9,90 | 16.830 | 247.000 | |
| 2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 13.100 | 1.924.850 | 0,69 | 9,72 | 127.341 | 18.710.889 | |
| 2004-10-06 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.400 | 23.250 | 6,41 | 9,72 | 13.609 | 226.006 | |
| 2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.400 | 1.911.750 | 1,03 | 9,59 | 186.046 | 18.333.682 | |
| 2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.100 | 21.850 | 10,63 | 9,59 | 20.139 | 209.542 | |
| 2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.892.350 | 0,48 | 8,96 | 80.680 | 16.963.972 | |
| 2004-10-04 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 19.750 | 5,33 | 8,96 | 8.964 | 177.049 | |
| 2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 22.100 | 1.883.350 | 1,19 | 7,69 | 169.843 | 14.473.921 | |
| 2004-09-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.400 | 18.750 | 14,68 | 7,69 | 18.444 | 144.098 | |
| 2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 23.400 | 1.861.250 | 1,27 | 7,17 | 167.734 | 13.341.626 | |
| 2004-09-15 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.500 | 16.350 | 18,05 | 7,17 | 17.920 | 117.198 | |
| 2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.300 | 1.837.850 | 0,23 | 6,85 | 29.455 | 12.589.272 | |
| 2004-09-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 400 | 13.850 | 2,97 | 6,85 | 2.740 | 94.872 | |
| 2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.833.550 | 0,49 | 6,84 | 61.563 | 12.542.032 | |
| 2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.000 | 1.824.550 | 0,50 | 6,84 | 61.537 | 12.475.178 | |
| 2004-09-01 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.000 | 13.450 | 8,03 | 6,84 | 6.837 | 91.963 | |
| 2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 700 | 12.450 | 5,96 | 5,84 | 4.091 | 72.765 | |
| 2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.200 | 1.815.550 | 0,34 | 5,84 | 36.237 | 10.611.164 | |
| 2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.500 | 11.750 | 62,07 | 5,83 | 26.214 | 68.447 | |
| 2004-08-20 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 40.500 | 1.809.350 | 2,29 | 5,83 | 235.925 | 10.540.007 | |
| 2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -200 | 7.250 | -2,68 | 5,50 | -1.100 | 39.875 | |
| 2004-08-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 200 | 7.450 | 2,76 | 5,10 | 1.020 | 37.995 | |
| 2004-08-16 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.500 | 1.768.850 | 0,14 | 4,75 | 11.875 | 8.402.038 | |
| 2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.300 | 7.250 | 46,46 | 4,72 | 10.850 | 34.202 | |
| 2004-08-13 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 21.300 | 1.766.350 | 1,22 | 4,72 | 100.483 | 8.332.756 | |
| 2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.800 | 4.950 | 130,23 | 5,67 | 15.889 | 28.090 | |
| 2004-07-21 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 25.652 | 1.745.050 | 1,49 | 5,67 | 145.567 | 9.902.635 | |
| 2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.400 | 2.150 | 186,67 | 5,89 | 8.242 | 12.657 | |
| 2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.648 | 1.719.398 | 0,74 | 5,89 | 74.468 | 10.123.300 | |
| 2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 750 | 750 | 5,96 | 4.472 | 4.472 | ||
| 2004-07-19 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.750 | 1.706.750 | 0,40 | 5,96 | 40.252 | 10.177.862 | |
| 2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Warrants |
P - Purchase | 97.500 | 97.500 | |||||
| 2004-05-18 |
|
4/A | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650.000 | 1.700.000 | 61,90 | 6,00 | 3.900.000 | 10.200.000 | |
| 2004-05-12 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 650.000 | 1.700.000 | 61,90 | 6,00 | 3.900.000 | 10.200.000 | |
| 2004-02-12 | 3 | ANTR.OB |
ANTARES PHARMA INC
Common Stock, $0.01 par value per share |
2.700.000 | ||||||||
| 2004-02-05 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -87.400 | 1.050.000 | -7,68 | 6,44 | -562.576 | 6.758.640 | |
| 2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -35.000 | 1.137.400 | -2,99 | 5,62 | -196.700 | 6.392.188 | |
| 2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 1.172.400 | -7,86 | 5,68 | -568.000 | 6.659.232 | |
| 2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -5.000 | 1.272.400 | -0,39 | 5,65 | -28.250 | 7.189.060 | |
| 2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -15.000 | 1.277.400 | -1,16 | 5,84 | -87.600 | 7.460.016 | |
| 2004-01-23 |
|
4 | BPA |
BIOSANTE PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 1.292.400 | -7,18 | 5,66 | -566.000 | 7.314.984 | |
| 2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
225.000 | ||||||||
| 2003-08-13 | 3 | BISP.OB |
BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 |
1.392.400 |
